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ABSTRACT 
N-linked glycosylation is the most common post-translational modification (PTM) of 
proteins that exist in nature. N-glycosylation and change in cells serve as a criterion to monitor the 
activity of developmental stages and diseases severity. Currently, there is an increasing application 
of mass spectrometry on glycoprotein for malicious, chronic or acute diseases, such as cancers, 
rheumatoid arthritis (RA) or influenza.  
In this dissertation, several mass spectrometric assays have been utilized to, quantitatively 
and qualitatively, characterize protein N-glycosylation at the glycan, glycopeptide and peptide 
levels. The goals are to identify serum-based RA biomarker (Chapter 2), or to determine possible 
glycan structures from monoclonal antibody (Chapter 3), or comprehensively to study one 
influenza glycoprotein, hemagglutinin (Chapter 4).   
 In Chapter 2, LC-MS/MS with CID as MS 2 is the primary technique that is applied to 
collect raw data for RA biomarker screening; western blot is the verification method for newfound 
biomarkers. This mass spectrometry based comparative analysis of N-glycoprotein in RA and 
healthy patients’ sera reveal 41 potential biomarkers for RA that can be applied in clinical research. 
Chapter 3 describes another LC-MS/MS based method developed for the structural analysis of N-
glycan released from the monoclonal antibody, immunoglobin G. Higher-energy collision 
dissociation (HCD) was the surprior technique utilized to identify glycopeptide fragments. The 
results show that 19 and 23 N-glycan structures were determined from standard and modified mAb 
samples respectively by using SimGlycan software, while 38 and 35 glycan structures were 
recognized by manually mapping respectively. 13 N-glycoforms, out of 26 overlapped glycan 
structures, were identified with significant alterations by comparing standard sample (sample A) 
and modified mAb (sample B) utilizing our method. In Chapter 4, we comprehensively studied 
hemagglutinin by using LC-MS/MS and MALDI from both proteomic perspective and glycomics 
prospective. After confirmed and verified protein sequence and glycosylation sites, galactose-
specific quantitation was performed with exoglycosidase digestion combined HPLC with 
fluorescence detection. The MALDI-MS/MS based method was utilized to confirm glycan 
structures.  
The results in this dissertation provide insights into the significance of protein 
glycosylation alterations as RA biomarkers, and these quantitative methods can be reapplied to 
any other disease biomarkers screening for clinical researchers.  
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CHAPTER 1.  GENERAL INTRODUCTION TO GLYCOMICS AND 
GLYCOPROTEOMIS 
Glycosylation, as one of the most important post-translational modifications, determines 
the activities and functions of these carbohydrate-binding proteins, also known as glycoprotein 
[1]. There are two major types of glycosylation in animal glycosylation: N-Glycosylation, in which 
sugar is attached to an asparagine residue, and O-Glycosylation. N-glycosylation related study is 
more advance-developed because one enzyme, called PNGase F, was discovered to release N-
glycan completely from their peptide backbone. Mass spectrometry is the dominate technology 
that is aggressively developing in order to comprehensively understand the structure-function 
relationship for glycoproteins [2].  
Glycome is an entire collection of glycans synthesized by a cell, tissue, or organism under 
specific conditions of time, space and environment [2]. The glycomics is the comprehensive and 
systematic analysis of the glycome. To achieve sensitive and definitive glycan analysis, mass 
spectrometry, especially high-throughput mass spectrometry, is widely utilized to analyze glycan 
structures in small sample quantities [3]. A tandem mass spectrum offers a list of M/Zs 
(mass/charge) from the fragments of the carbohydrates. Meantime, the spectrum is capable for 
database searching by matching each fragment ion. However, the challenge in structural 
characterization of glycome is to identify the linkage between each monosaccharide. For this 
purpose, permethylated or isotope-labeled glycan generates a significant quality of fragments in 
the mass spectrometer as a perfect resource for determining glycan connectivity. Furthermore, an 
alternative method for requiring structural information is the stepwise removal of terminal 
monosaccharides through the use of exoglycosidases [4] (Chapter 4.3). 
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Glycoproteome is an entire collection of glycoproteins that exist in a cell, tissue, or 
organism under specific conditions of time, space and environment [2]. The field of 
glycoproteomics is designed to identify the peptides with sugar moiety attached. There is an 
increasing research interest in studying the changes in the expression of one glycosylation site or 
glycoprotein globally (Chapter 2). In general, a general design of glycoproteomic experiment 
involves enzyme digestion of either simple or complex sample, followed by enriching the 
glycopeptides. Sample are further treated with deglycosylation procedures and analyzed by a high-
throughput mass spectrometer. Many proteomic techniques have been adopted in the 
glycoproteomic analysis, like SILAC (stable isotope labeling by amino acids in cell culture) [5] or 
18O combine with enzymes.  
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CHAPTER 2. COMPARATIVE PROTEOMIC STUDY OF N-GLYCOPROTEIN 
BIOMARKERS IN RHEUMATOID ARTHRITIS PATIENTS’ SERA  
2.1 Introduction 
Rheumatoid arthritis (RA) is a chronic multisystem autoimmune disease, thus causing a 
systemic inflammation of many tissues and organs, but principally, flexible joints and surrounding 
tissues [6]. To date, no one has been able to determine the exact cause of this peculiar effect, but 
there is a theory that RA is most likely resulting from several factors combined, such as genetic 
factors or environmental triggers [7]. Up to now, the complicated problem is that it is challenging 
to find a way to stop the manifestation of this disease in the human body because various inducing 
factors are involved in the disease progression. So far, many classes of biomarkers have been 
discovered: they can come from clinical, imaging patterns, or biochemical parameters. However, 
none of them work properly as a monitoring factor for the disease process or as a most valuable 
biological signal for the response of treatments. According to the reason as mentioned above, the 
discovery of early stage diagnosis biomarkers is critical to relieving patients from suffering. 
The valuableness of these biomarkers is noteworthy; however, the high specific RA 
biomarker was not included in the American College of Rheumatology (ACR) or the European 
League against Rheumatism (EULAR) diagnostic criteria until earlier 2000s. The reason is that 
several high expression proteins in arthritis have a single strong associations with one particular 
type of arthritis family disease, such as ACPA, related to patients with HLA-DRB1 genetic 
disorder [8] and C-reactive protein or cytokines (associated with inflammation) [9]. Without long-
term experimental trial testing, those so-called biomarkers are not capable of fulfilling the 
specificity and sensitivity, the main criteria of biomarkers [9-11]. 
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N-linked glycosylation is the most common post-translational modification (PTM) of 
proteins. In fact, the majority of serum proteins are believed to be glycosylated. N-glycosylation 
and its related changes serve as a criterion to monitor the activity of developmental stages and 
diseases severity [12-14]. Thus, an extensive correlation exists between many human diseases and 
the changes in the glycosylation of accompanying glycoproteins, such as cancers [15-18], 
cardiovascular diseases and immune deficiency diseases [19-22]. Hence, a thorough inspection of 
RA serum N-glycosylated proteins might endow the potentiality to reveal hyper- or hypo-
expressed proteins associated with RA early diagnosis and pursue targets for selection or response 
monitoring of therapy [22, 23]. 
Label-free protein quantification is one of two major quantitative proteomics approaches 
beside stable isotope labeling techniques [24]. More recently, there is a booming interest in label-
free protein quantification applications. Two major label-free quantification strategies, peak area 
or signal intensity measurement and spectral counting procedure, are widely applied into bottom-
up proteomics. Even though label-free approaches offer the lowest accuracy among other 
quantification techniques, they superiorly have improved quantitative proteome coverage, 
simplified sample preparation procedures, and increased capability to quantitate multiple proteins 
in one experiment with relatively small sample quantity, regardless of the protein concentration 
[24, 25]. Thus, label-free quantitative techniques are more suitable for precious complex samples 
such as plasma or serum, body fluids, or tissue exactions. At the same time, label-free quantitative 
methods can offer a global view of understanding high expression proteins as a unique disease 
condition related change, instead of concentrating on one particular over-expressed protein [24]. 
Paralleled to label-free quantification, isotope labels are usually introduced into samples by using 
spiked synthetic peptides as external standards, or into systems metabolically, chemically or 
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enzymatically as an internal standard [26]. However, the cost of isotope labels for these techniques 
can be unreasonable, and the requirements, like specific software and training or expertise to 
process data can cost a fortune. Meanwhile, these stable isotope labeling techniques are not 
suitable for all sample types, and the capability to analyze multiple isotope-labeled samples in a 
single trial is constrained by those technologies. Theoretically, stable isotopic labels aim to ingrate 
with every reactive amino acid to generate a mass tag [27]; in contrast, the practical aspect of full-
labeling is hardly reached [28]. 
Our study was structured to report a method to identify proteins and glycoproteins 
exhibiting significant alterations of their expression between RA patients and healthy human sera 
via label-free quantification technique. Two groups of samples were treated with filter added 
sample preparation (FASP) and trypsin digestion respectively, followed by zwitterionic 
hydrophilic interaction chromatography (ZIC-HILIC) enrichment and collision induced 
dissociation (CID) fragmentation by using Orbitrap Elite MS/MS. The generated raw files were 
mapped to peptide sequence and N-glycosylation sites through pFind software. The results showed 
that 92 proteins, including 39 glycoproteins, were identified with significant variations in RA 
patients’ serum samples. Meanwhile, 41 distinctly expressed (over 2-fold range) proteins, 
including 28 N-linked glycoproteins, were discovered by means of our method (complement factor 
B is overlapped). Further, this approach is an affordable, feasible and capable technique for 
pathological specimens’ studies. It offers a simple and fast manner for early stage diagnosing and 
disease progression monitoring for particular conditions that are associated with over-expressed 
proteins. 
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2.2 Materials and Experiments 
2.2.1 Materials and Chemicals 
Materials: Peripheral blood samples were received from 20 patients with RA at Peking 
University People’s Hospital in Beijing, China, and all were collected at 6 am and processed within 
18 h of collection. The sera were split into aliquots and stored at −80°C until use. All patients met 
the ACR 1987 revised criteria for RA classification and had active arthritis at the time of sampling 
[29]. Detailed demographic and clinical characteristics were listed in supplementary material.  
Chemicals and Enzymes: Peptide-N-glycosidase F (PNGase F) was purchased from New 
England Biolabs (Ipswich, MA), formic acid (FA) and urea and ammonia bicarbonate solids were 
obtained from Sigma-Aldrich Co. (St. Louis, MO). ZIC-HILIC media was bought from Merck 
(Merck, Germany). Sequencing grade porcine trypsin was purchased from Promega (Madison, 
WI); deionized water was produced by a Milli-Q A10 system from Millipore (Bedford, MA). 
Optimal LC-MS grade acetonitrile (ACN) and same grade water were purchased from Thermo 
Fisher Scientific, Inc. (Waltham, MA). Dithiothreitol (DTT) was obtained from Promega, and 98% 
Iodoacetamide (IAA) was acquired from Alfa Aesar (Ward Hill, MA). 3M Empore C8 disk was 
bought from 3M Bioanalytical Technologies (St. Paul, MN). The YM-30 (30 kD) and YM-3 (3 
kD) filtration devices were purchased from Millipore. Western blot was performed by the Original 
iBlot® Gel Transfer Device from life technology, Thermo Fisher Scientific, Inc. The following 
commercial antibodies were purchased for Western blot analysis of result verification: rabbit anti-
human complement factor B antibody, rabbit anti-human Serum Amyloid A (SAA) antibody and 
antibody horseradish peroxidase (HRP)-linked antirabbit IgG were purchased from Abcam plc. 
(Cambridge, MA). ECLplus reagent chemiluminescence detection system was obtained from GE 
Healthcare (Waukesha, WI). 
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2.2.2 Filter-Aided Sample Preparation (FASP) 
Same portions of ten RA patients’ human sera were pooled to reduce the individual 
difference. A same number of Healthy human sera were treated by following the same procedures. 
Approximately 100 µg of serum (10 µL) was included in each sample according to Nanodrop 2000 
Spectrophotometer manufactured by Thermo Fisher Scientific. Following the FASP protocol 
previously reported by Wisnewski et al. [30]. Specimens were mixed thoroughly with 20 µL of 
lysis buffer (20 mM Tris-HCl, 4% (v/v) SDS, 100 mM DTT, pH 7.6) followed by a 5-minute 
incubation at 95 °C. An amount of 270 µL of Urea solution (8 M urea in 0.1 M Tris/HCl, pH 8.5) 
was combined with each protein solution before transferring the entire volume of RA and healthy 
human sample mixtures into two separate 30kDa Microcon filtration devices. After an hour of 
14000g centrifugation, 100 µL of Urea solution was deposited into each filter unit, and then the 
centrifugation was then resumed for 10 minutes twice. Followed by another centrifugation step, 
the concentrates were combined with 100 µL of 50mM IAA in Urea solution and the units were 
incubated in darkness at room temperature for 30 minutes. After twice of Urea solution 
addition/centrifugation process, the systems were equilibrated twice with 100 µL of 50 mM 
ammonia bicarbonate (Elution Buffer). Additionally, centrifuging the units to dead volume was 
preferred, theoretically less than 20 µL remains inside the filter. 100 µL elution buffer was added 
to each filter unit, followed by adding 2 µg trypsin. The digestion process was accomplished at 37 
°C for 12 hours. To fully elute desired trypsinized peptides, the filter units were rinsed with 50 µL 
elution buffer under centrifugation for five times. Millipore ZipTip pipette tips with C18 resin 
were applied for desalting the samples before LC-MS/MS analysis. Desalted peptides were dried 
in a vacufage and stored in the -80°C refrigerator for future MS detection. 
  8 
2.2.3 N-Glycopeptides Enrichment and Simplification 
Approximately 50 µg of pre-dried digested peptides were added into 10 mg ZIC-HILIC 
media and enriched by following the previously published procedures [31]. The entire enrichment 
processes were in one self-made tip-size column. The detailed strategy is as follows: C8 extraction 
disk was loaded into a 200-µL pipet tip; afterward, ZIC-HILIC media was suspended in 100 µL 
acetonitrile and injected into tips. Digested peptides were re-dissolved in binding buffer (80% 
ACN, 0.5% FA) and loaded onto the ZIC-HILIC 200 µL-prepacked tip with six times equilibrating 
procedure by using100 µL binding buffer. Bounded peptides were eluted twice with 80 µL elution 
buffer (99% H2O, 1% FA), then speed-vacuumed until dry. The enriched N-linked glycopeptides 
were resuspended in 50 µL G7 buffer (50 mM Sodium Phosphate, pH 7.5) and incubated with 
peptide-N-glycosidase F (N-glycanase F, PNGase F) for 12 hours under 37 °C for deeper 
enzymatic reaction. The well-prepared samples were dried by a vacufuge vacuum concentrator 
and stored in a refrigerator at -80 °C for further LC-MS/MS analysis. 
2.2.4 LC-MS/MS Analysis 
Reverse-phase nano-HPLC-MS/MS data were obtained on an LTQ-Orbitrap Elite mass 
spectrometer (Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 
high-performance liquid chromatography system (Thermo Fisher). EASY-Spray PepMap C18 
Column was a separation unit with a length of 50 cm capillary filled with a C18 reversed phase 
particles (EASY-Spray Column PepMap C18; particle size, 2 µm; pore size, 100 Å; 
ThermoFisher). Separation was achieved by a mixture of mobile phase A (99.9% H2O, 0.1% FA) 
and phase B (79.95% ACN, 19.95% H2O, 0.1% FA. The linear gradient was from 5 to 50% buffer 
B for 300 min at a flow rate of 300 nL/min. LTQ-Orbitrap Elite mass spectrometer was operated 
in the data-dependent mode. A full-scan survey MS experiment (m/z range from 375 to 1600; 
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automatic gain control target, 1e6 ions; resolution at 375 m/z, 60,000; maximum ion accumulation 
time, 10 ms) was acquired by the Orbitrap mass spectrometer, and ten most intense ions were 
fragmented by collision induced dissociation (CID) in the octopole collision cell. The CID 
fragment ion spectra were acquired in the ion trap analyzer with a resolution of 60,000 at m/z 500 
(automatic gain control target, 1e4 ions; maximum ion accumulation time, 10 ms). The MS2 scan 
model was set as the centroid. The other conditions used were: normalized collision energy is 35, 
default charge state is 3, and activation time is 5 ms. 
2.2.5 Data Searching and Data Annotation for N-Glycoprotein and Protein Analysis 
In this work, the MS spectra were searched under the human database downloaded from 
Uniprot_swissprot plus Uniprot_TrEMBL (Released on 2012-04, human, 65493 entries), linked 
with reversed version of all sequences. According to Ma et al. (2013), all of the asparagine (N), 
potential glycosylation sites, in sequence N-!P-[S|T|C] (where !P is not proline) were replaced with 
J for database searching and easier data analysis purposes [31]. The definition of J was the 
modification of N with 0.9850 mass tags, which is another symbol of aspartic acid (D). The raw 
data was compared and matched to UniProt human database by using pFind 2.1 search engine [32] 
with static modification of Carbamidomethyl (Cys), dynamic modification of J_0.9840 (N 
position), Deamination (N), Oxidation (Met) and Acetylation (Lys). Trypsin was picked for 
digestion with an allowance of two missed cleavages. The mass tolerance of the precursor ion was 
adjusted to 20 ppm while 0.8 Da was applied for the fragment ion. A false discovery rate (FDR) 
of 1% was estimated and implemented to all data sets at the total peptide level. Furthermore, the 
pBuild software was assigned to remove redundant protein entries and to group related proteins 
into a single group entry. All the data was assessed for the student test, and then a list of proteins 
with significant variation based on p-value was generated. The DAVID functional analysis tool 
  10 
(http://david.abcc.ncifcrf.gov/home.jsp) was applied to derive pathways and protein distribution 
to track identified serum N-glycosylated proteins [33]. The published work of Ma et al. (2013) was 
adopted in this study for searching and annotating proteins with some minor [31] with some minor 
modification to reach higher proteome coverage. The modification-settings were optimized as 
following. The static modification is Carbamidomethyl (Cys), and the dynamic ones were 
Deamination (Asn), Oxidation (Met) and Gln to pyro-Glu (Any N- terminal started with Q).  
2.2.6 Verification of Protein Lists with Significant Difference from N-Glycoprotein 
and Protein Data Analysis – Western Blot Assay (WBA) 
The entire verification experiment was following the standard procedure of Western-blot 
assay [34]. The protein contents of sera were adjusted to 1.5 mg/ml with deionized water under 
Nanodrop 2000 monitoring. The units were boiled in 4X NuPAGE LDS protein sample buffer 
(Thermo Fisher) for 10 minutes and centrifuged under 12,000xg under 4 oC. An equal volume of 
each diluted sample was loaded on 4-12% NuPAGE, Bis-Tris, 0.75 mm thick gels with 10 wells 
(Invitrogen). The electrophoresis was run in running buffer at 180 V for 1 h and transferred to 
Nitrocellulose Membrane by using iBlot® Transfer Stack (Thermo Fisher). The membrane was 
blotted in 5% nonfat dry milk in 0.1% Tween-20, 150mM NaCl and 50mM Tris, pH7.6(TBST) 
for 2 hours and incubated Over-Night with anti-complement factor b antibody, diluted 1:10000, or 
anti-serum amyloid A antibody with 1: 1000 dilution ratio, followed by three times 5-minute 
washing steps in TBST. Afterward, the entire membrane was incubated for one hour with antibody 
horseradish peroxidase (HRP)-linked antirabbit IgG under 1:5000 dilutions in blocking buffer. 
With carefully three-time rinsing, the membrane was detected under ImageQuant Las 4000 (GE 
Healthcare life sciences) after incubating with ECLplus reagent chemiluminescence detection 
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system (GE Healthcare) for 3 minutes. ImageQuant Las 4000 was applied in capturing and 
modifying the images. 
2.3 Results 
2.3.1 Label-Free Quantification Strategy for N-Glycoprotein and Protein Sample 
In order to obtain the essential data, two sets of experiments were triplicated following the 
label-free quantitative technique. The entire experimental workflow used in this study is shown in 
Figure 2.1. Equal aliquots (200 µg) of 10 serum samples extracted from different healthy and RA-
diseased individuals were separately mixed into one pooled sample. For N-glycoprotein analysis 
(in blue), the strategy of detection is to identify the glycopeptides with glycosylation sites. In the 
course of the procedure, proteins were digested with trypsin using FASP protocol followed by 
ZIC-HILIC enrichment to bind selectively digested glycosylated peptides [2]. Subsequently, 
glycopeptides were digested by PNGase F to remove N-linked glycans; it changed asparagine 
(Asn) to aspartic acid (Asp) and left a mass tag with 0.9840 Dalton difference. Simplified 
glycopeptides were analyzed with a high-precision Orbitrap Elite. Similar workflow (in green) was 
applied again on the total proteins without investigating glycosylation sites. The merged samples 
were studied under the collision-induced dissociation (CID) technique. All the spectra were 
matched with human protein database of using pFind studio 2.0. The obtained protein list was 
generated after statistic calculation and comparison; Western-blot assay was the primary technique 
to verify the selected abundant proteins among the list in different groups of samples. 
2.3.2 Database Searching and Data Comparison of Site-Specific Glycosylation 
Occupancy between N-Glycoproteins 
On average, a total of 855 matched peptides of 653 proteins were identified in NHS. Of 
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those, 297 N-glycosylated sites in 134 glycoproteins with the sequence N-!P-[S|T] (where !P is 
not proline) were detected in NHS. Additionally, 540 proteins with 577 peptide fragments were 
recognized in RAHS from three trials for site-specific N-glycosylation expression analysis. 
Furthermore, a sum of 294 N-glycosylated sites in 132 glycoproteins was found in RAHS. In total, 
an intersection of 254 N-glycosylation sites from 119 N- linked glycoproteins was identified 
between RAHS and NHS categories (Figure 2.2). The enriched N-glycopeptides were evaluated 
through pFind software to confirm and score peptide sequences. From run to run, #2 and #3 sample 
runs were more alike according to spectra similarity between rheumatoid arthritis and healthy 
volunteer specimens (Negative Control). 
 
Figure 2.1 The Scheme to Identify the Difference in N-Glycoproteins and Serum Total 
Proteins 
The identifications workflow of N-glycoprotein and serum total protein with significant expressive 
variances between rheumatoid arthritis and normal human sera is shown above. 
Based on the statistic comparisons, Student’s t-test, between RAHS data and NHS data, 53 
N-glycosylation sites from 39 glycoproteins had significant differences between RA serum 
samples and normal serum samples (p-value< 0.05). Of those, three proteins were very highly 
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significant (p < 0.001), while 12 proteins were identified with highly significant (0.001< p < 0.01). 
Furthermore, a total of 35 N-glycopeptide fragments within 28 glycoproteins listed in 
supplementary information had abundance variations significantly (over 2-fold difference) 
between RAHS and NHS. Of the information above, 27 N-linked glycopeptide fragments from 22 
glycoproteins were hyper-glycosylated, or the expressions of these 22 proteins in RAHS are more 
than two times higher than the one in NHS. Meanwhile, 8 N-linked glycopeptides from 7 
glycoproteins were hypo-glycosylated or down-expressed on the basis of the statistic result. The 
microarray result obtained by MeV software and the two-color T-Test image is attached below in 
Figure 2.3. During N-glycoprotein comparison study, two N-glycosylation sites were 
distinguished from four proteins respectively, complement C4-A or B, ceruloplasmin, 
apolipoprotein B-100 and α-1-antitrypsin; while, four unique high expressed N-glycosylated 
peptides were identified from α-1-antichymotryps in total. The entire list of 35 N-linked 
glycopeptides is listed in the supplementary material in the order of their alteration ratios.  
2.3.3 Database Searching and Data Comparison for Proteins Identified with 
Alteration in Global Perspective 
Without using the ZIC-HILIC enrichment technique, analysis of trypsin-digested proteins 
showed a broader and more accurate image of proteins with expression variation that are disease-
related. In healthy volunteer human serum, an average of 786 proteins was identified. While, an 
average of 795 proteins was revealed in this step from rheumatoid arthritis patients’ sera with a 
total of 247 proteins in common between sample groups after removing unreview proteins. Based 
on the statistic comparisons between two sets of data, RAHS and NHS, 53 proteins were reliable 
(p<0.05); of the 53 proteins, three proteins were very highly significant (p< 0.001), and 19 proteins 
were identified with high significance (0.001<p< 0.01). Besides, 14 proteins had major changes in 
  14 
relative protein global expression ratios (Figure 2.4). The RA triplicates were more similar 
between sample-run #1 and #3; additionally, two triplicates in the negative control (NHS), run #2 
and #3, were significantly alike. The variations between these 14 selected proteins were attached 
to the supplementary information.  
 
Figure 2.2 The Overlapped Lists between Rheumatoid Arthritis and Normal Volunteer in 
Both Assays 
Two lists of components shared that generated from the results from normal human (NHS) and 
rheumatoid arthritis (RAHS) is shown above. The one on the left is the pool where the candidates 
of N-Glycosylation sites chosen from; the right figure is the list where protein with global 
expression difference were selected. 
2.3.4 Protein Verification by Western Blot Assay (WBA) 
We selected complement factor B and serum amyloid A protein respectively as an N-linked 
glycoproteins group and a protein expression group to validate our assumptions, according to 
antibody commercially availability. The affinity of complement component C4 is inefficient 
despite the fact that one site is higher glycosylated. To pursue more reliable protein-concentration 
differences, both antibodies were selectively bound to protein, neglecting glycoforms. Since 
glycan observed from certain glycoproteins alter during diseases [35], therefore, antibodies 
targeting a specific glycoform are not reliable to verify the amount of protein when glycan 
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modifications take places simultaneously. During the procedure, different sets with the same 
protein amount (200 µg) of the ten RA patients’ sera were loaded and verified single with the same 
quantity of normal human sera by following Mahmood’s and Yang’s instructions [34]; protein 
concentrations were measured with Nanodrop after the samples thawed thoroughly. Since Western 
blot is a technique that is designed to qualify for semi-quantitative analysis, it offers a relative 
comparison of protein expression level on the same membrane [36]. While NHS and RAHS both 
contain complement factor B and serum amyloid A protein, it is helpful to compare them 
simultaneously for both interest proteins.   
Since the antibody we chose, anti-complement factor B antibody, was specifically targeting 
the protein, marked in Figure 2.5 as complement factor B. Typically, glycoprotein forms several 
bands because of glycosylation occupancy variety, which was confirmed by Figure 2.5 underneath 
[2]. The differences in intensities between NHS and RAHS are not significant; based on our 
analysis, the protein expression of complement factor B in 10 pooled RAHS were 2.2 times more 
distinct than NHS. This observation might be because the antibody is aiming to complement factor 
B instead of glycan parts of targets, and these individual differences were balanced by merging 
sample preparation.  
Serum amyloid A protein (SAA) is an inflammation associated protein that belongs to the 
acute phase protein category. During acute inflammation, the serum SAA level can dramatically 
increase over one 1000-fold in mice as an immune defense [37-39]. In our study, serum SAA level 
in 10-pooled RA sera was over 10-fold higher than its level in serum of volunteers. However, there 
are barely enough records about our donors concerning the disease statuses, which varies based on 
each health conditions, lifestyle, age, or gender individually. This information can explain that 
why some RA patients’ sera almost have the same band darkness as the healthy ones in Western 
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blot assay, which is shown in Figure 2.5 as well. 
To confirm the accuracy and sensitivity of our techniques, two random spectra from 
complement factor B and serum amyloid A protein were chosen to conduct tandem mass spectra-
peptide matching. The peptide-spectra mapping results are as following in Figure 2.6 and Figure 
2.7. 
 
Figure 2.3 A List of Glycosylation Sites Identified with Expression-Alternations 
35 N-glycosylation sites were identified with significant expression difference. 27 peptides were 
overly expressed, and 8 glycopeptides were down-regulated. (p<0.05) Complement factor B was 
selected for verification process accordingly. Multiple glycoproteins here were identified from 
complement system.  
  17 
 
Figure 2.4 A List of Proteins Identified with Hyper- /Hypo- Expressions 
14 serum protein expression ratios have a quite broad range from 14-fold over-expression to 4-
fold down-expression; among those, 10 were overly expressed, and 4 proteins were down-
regulated (p<0.05). Serum amyloid A protein was selective for validation procedure. 
 
Figure 2.5 WBA Verification Results of CFB (Top) and SAA (Bottom) 
Complement factor B (Top) was selected to verify the significance and our assumption of the 
complement system. Serum amyloid A protein (Bottom)’s result confirmed our theory. 10 samples 
were loaded independently; four normal sera were run on the left, and the rest four on the right 
were RA patients’ sera with two protein ladders. (One is on the left, and one is in the middle.) The 
apparent molecular masses of prominent bands in kilodaltons (kD) are marked on the left.  
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2.4 Discussions 
Based on our initial statistical results on the occupancy of glycosylation sites in proteins, 
several sites were identified with hyper-/hypo-glycosylated between NHS and RAHS. However, 
judging singly by the difference of occupancy of N-glycosylation sites was hardly robust eought 
to support the conclusion that rheumatoid arthritis changes the distribution of glycan moieties in 
candidate proteins; this was the reason we designed the second part of the experiment. We 
hypothetically made two assumptions: first, the changes (increase/decrease) in glycan occupancy 
discrepancy might be related to rheumatoid arthritis. In more detail, the elevation or demotion of 
glycosylation among these sites is not consistent with the adjustments of identical protein 
expression. Thus, these glycosylation sites among glycoproteins are specific targets for clinical 
rheumatoid arthritis diagnostics. Second, RA prompted immune system, or any other body self-
defense system results in globally increasing/decreasing expressions of proteins from a particular 
catalog, for example, cytokines and acute phase proteins [40, 41], in order to control disease 
progression. If so, the adjustments of proteins simultaneously alter the ratios of N-linked 
glycosylation sites. Some examples are given in supplement materials that explain how the results 
match our theory. 
One protein, α-1-antitrypsin, had an elevated expression on one glycosylation site (N271) 
which is over 3.3 times. Simultaneously another peptide (N70) was decreased over 5-fold. In the 
meantime, the expression of α-1-antitrypsin globally elevated 1.39 times which is not consistent 
with either of the modifications stated above. Based on the above result, RA caused the occupancy 
of glycosylation site of α-1-antitrypsin to differentiate from NHS. In conclusion, α-1-antitrypsin 
was mainly modified in the glycosylation site occupancy that was unrelated with α-1-antitrypsin 
protein elevation, which was our first assumption. Two N-linked glycosylation sites identified with 
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noteworthy differences matched the result. Asn70 and Asn271 were known as the glycosylation 
sites for α-1-antitrypsin [42, 43], but the confirmation of RA-associated alteration of glycosylation 
occupancy has not been reported yet. Works of literature have qualified α-1-antitrypsin as a 
biomarker for multiple diseases, which are usually accompanied by inflammation symptoms, such 
as lung cancer, breast cancer, or arthritis-related disorders [44-48]. Focusing on glycosylation sites 
occupancy alternation for arthritis-related diseases is more accurate and observable than an 
emphasis on the protein backbone expression. 
Αlpha-1-antichymotrypsin is an acute phase protein generated in the liver during 
inflammation, and it is from the same protein subgroup as α -1-antitrypsin [49]. Based on our mass 
spectrometry results, there were three asparagine residues—Asn106, Asn127, and Asn271—out 
of six N-linked glycosylation sites with no confirmation of the other three positions —Asn33, 
Asn93, Asn186— in our analysis [50, 51]. Two of three glycosylation sites, Asn271 and Asn127 
with elevated 4.70-fold and 4.15-fold respectively, had significantly higher glycan occupancies 
compared to protein backbone expressional elevation (1.88 times). Meanwhile, Asn106 was 
slightly elevated to 2.73 times. The latter is practically reliable with the elevated expression of α-
1-antichymotrypsin. 
Similar statistical treatment of the results was applied to protein global expression study. 
By combining the results from N-glycoprotein and total protein analysis together, a total of 7 
proteins from the complement system were identified with significant alternations, which 
exceeded 19% of protein identifications. 6 glycoproteins from the complement system had 
glycosylation occupancies changes after patients were diagnosed with RA; at the same time, three 
proteins among these 7 were greatly expressed in RA patients’ sera (Table.1.2). 
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Figure 2.6 Example Tandem Mass Spectra Showing Matches to One Peptide in Complement Factor B Protein 
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Figure 2.7 Example Tandem Mass Spectra Showing Matches to One Peptide in Serum Amyloid A Protein
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The complement system is comprised of plenty of unique plasma proteins that play a 
substantial role in immune system. A huge portion of these complement proteins is enzymes that 
are activated by proteolytic cleavage, and consequently, the activity triggers a chain acute 
inflammatory event [52]. A list of literature has approved that the levels of complement C1q-C4 
proteins from classical pathway were significantly elevated in patients with RA compared to those 
patients with RA in clinical remission by 2-fold difference [53]. The result discovered here gives 
undeniable evidence that the complement component C4, a glycoprotein, has over 14-times higher 
glycosylation occupancy variance compared to a 1.5-fold increase in protein expression globally, 
which matches the number motioned before. Complement factor B is another example of the 
intermediate from the alternative pathway. During the alteration, complement factor B breaks into 
complement factor Ba and Bb, regulated by complement factor H; complement factor H is crucial 
to the homeostasis of complement system for protecting tissues from damage by complement 
activities. Complement factor B is highly expressed and -glycosylated while RA develops. Unlike 
complement factor B, factor H maintains its normal protein level but hypo-glycosylated, according 
to our results. Thus, we have assumed that up-glycosylated complement factor B decreases the 
associate activity to associated with factor C3b, which hinder the further activity [54]. 
Hypothetically, glycosylated factor B incompletes the pathway to form Ba or Bb, further impeding 
factor H to precede the protective function. Research has indicated that down-glycosylated factor 
H may lose regulation control of complement activation [55-57]. In the meantime, our study proves 
the previously mentioned theory; even though the level complement factor H maintained the same, 
the down-glycosylation of factor H might associate with the severity of RA. Complement 
component C7, C8, and C9 are the terminal components of the complement system, while C7 
serves as an anchor for C8 and C9. Hence, the expression of these three proteins—C7, C8, and 
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C9—remain at the same level as literature has approved [58]. The variations of complement system 
proteins indicate that the progression of RA associated with complement system activation; 
besides, complement component C4 or complement factor B combined with factor H could be 
exploited as potential biomarkers for RA diagnosis. The changes of each protein from complement 
system are concluded here in Table 2.1. 
 Table 2.1 The Expression Differences between N-Glycoproteins from Complement System 
Protein name Change (▲/▼) 
Glycan Occupancy 
Change Ratio 
Protein Expression 
Change Ratio 
Complement C4-A ▲ 14.5 1.5 
Complement factor B ▲ 9.8 2.2 
Complement component C7 ▲ 2.2 1.4 
Complement component C9 ▲ 7.9 2.7 
Complement component C8 
gamma chain 
▲ - 2.0 
Complement factor H-
related protein 3 
▲ 2.9 1.9 
Complement factor H ▼ 0.18 1.3 
The comparisons of proteins from complement system are showing a significant difference 
in their glycosylation occupancies. The variances from our results follow the complement system 
functional mechanism, which is robust support for our study. 
2.5 Concluding Remarks 
In this study, we established a novel method to discover 41 potential biomarkers, among 
which 28 are glycoproteins, of rheumatoid arthritis. Complement system proteins showed 
significant changes during RA progression in our study; furthermore, the variations of these target 
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proteins matched complement pathway mechanism; this robustly supports our discovery and the 
hypothesis of complement system functions in RA. As one example, the proteins complement 
component C4 and complement factor B with distinct changes can be used as both a diagnostic 
technique and a monitor of therapeutic drug efficiency. Consequently, further study of these 
proteins may reveal a new method to diagnose rheumatoid arthritis, which may potentially revert 
RA from incurable to treatable when the patients are confirmed in the early stage of the disease. 
In addition, our method may offer a different prospect to predict thoroughly and screen potential 
biomarkers in any other diseases from acute life-threatening to chronic pain-suffering.   
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2.6 Complementary Materials 
2.6.1 Clinical Characteristics of Patients with RA 
Peripheral Clinical human sera, including healthy human serum samples and rheumatoid 
arthritis patient sera, were supplied by Peking University People’s Hospital (Beijing, P.R. China). 
Previous institutional ethical approval was obtained and the healthy volunteers in the study gave 
their written informed consent. Ten RA patients’ human sera and ten normal human sera were 
equally merged into two mixed sample units respectively in this study. The ethics committee 
approved the research protocol. 
Table 2.2 Clinical Characteristics of Patients with RA 
Age, median (range) years 54 (34-77) 
Female, no. (%) 16 (80) 
Smoker, no. (%) 4 (20) 
Disease activity  
RF+, no. (%) 14 (70) 
anti-CCP+, no. (%) 14 (87.5) 
ESR, median (range) mm/h 52 (17-111) 
CRP, median (range) mg/dl 24.7 (6.12-229) 
Tender joint count (TJC), median (range) 2 (0-22) 
Swollen joint count (SJC), median (range) 6 (1-34) 
Therapy  
Prednisone, no. (%) 11 (55) 
NSAIDs, no. (%) 10 (50) 
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cDMARDs, no. (%) 13 (65) 
bDMARDs, no. (%) 2 (10) 
bDMARD, biological DMARD; CCP, cyclic citrullinated peptide; 
cDMARD, conventional DMARD; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate; NSAID, non-steroidal anti-inflammatory drug; RA, 
rheumatoid arthritis; RF, rheumatoid factor. 
2.6.2 N-glycosylation Variations Are Caused by Protein-Specific or Site-Specific 
Table 2.3 Comparison Between N-Glycosylation Sites (NS) Analysis and Protein Expression 
(PE) Analysis 
Protein 
ID 
Protein 
N-linked glycopeptide 
glycosylation sites 
RA/Normal 
Ratio (NS) 
RA/Normal 
Ratio (PE) 
P00751 Complement factor B 
ALQAVYSMMSWPDDVPP
EGWJR 
10.4 ± 2.2 2.2 ± 0.2 
P02748 
Complement 
component C9 
JETYQLFLSYSSK 5.0 ± 0.6 2.7± 0.3 
P80108 
Phosphatidylinositol-
glycan-specific 
phospholipase D 
GEEDFSWFGYSLHGVTVD
JR 
1.4 ± 0.5 0.36 ± 0.1 
Table 1.3 includes several glycoproteins (partial list) from N-glycosylation sites’ alteration over 
two-fold variances during the statistical comparison between patients and normal healthy donor. 
(RAHS/NHS> 2 – fold or RAHS/NHS< 0.5 – fold), meanwhile, the list on the right is from protein 
expression comparison. By paralleling these two lists, several conclusions can be made. 
In Table 2.3, several glycoproteins are partially selected from the result list of N-
Glycosylation sites’ alteration over two-fold variances during the statistical comparison between 
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patients and normal healthy donor (RAHS/NHS> 2 – fold or RAHS/NHS< 0.5 – fold). On the 
basis of our first assumptions, the alteration of glycosylation sites occupancy is associated with 
either protein expression or single glycosylation sites occupancy changes. Therefore, all three 
proteins – complement factor B, complement component C9, and Phosphatidylinositol-glycan-
specific phospholipase D – are relatively hyper-glycosylated in these three glycosylation sites with 
slight changes in their protein expressions. 
Partial result list from N-Glycosylation sites and protein expressions comparisons with 
significant difference (p-value<0.05) were chosen to support our protein-level specific alteration 
assumption. N-glycosylation site occupancies elevate in the approximate rate as the protein 
expressive ratio, which is consistent with the increasing in protein expression (the difference is 
less than or equal to 0.2). Therefore, these proteins are associated with rheumatoid arthritis 
progression that triggers immune reactions, i.e. inflammatory or auto-immune diseases behaviors. 
Table 2.4 Protein Comparison between N-Glycosylation Sites (NS) Analysis 
and Protein Expression (PE) Analysis 
Protein 
ID 
Protein 
N-linked glycopeptide 
glycosylation sites 
RA/Normal 
Ratio(NS) 
RA/Normal 
Ratio (PE) 
P00738 Haptoglobin 
MVSHHJLTTGATLINEQWL
LTTAK 
2.0 ± 0.2 1.9 ± 0.3 
P00751 
Complement 
factor B 
SPYYJVSDEISFHCYDGYT
LR 
2.0 ± 0.2 2.2 ± 0.2 
P01871 
Ig mu Chain C 
region 
GLTFQQJASSMCVPDQDT
AIR 
1.9 ± 0.5 1.7 ± 0.3 
Table 2.4 includes several proteins (partial list) from both methods with statistical significance. 
By paralleling these two lists, the results support our second assumption. 
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2.6.3 Complete Lists of T-Test Results from N-Glycoprotein Comparisons Site-
Specific and Globally 
In Table 2.5, we listed the overlapped glycosylation sites with significant differences 
between rheumatoid arthritis patients’ sera and normal healthy sera. 53 N-glycosylation sites from 
39 glycoproteins have significant differences between RA serum samples and normal serum 
samples (p-value< 0.05); of those, 3 proteins were very highly significant (p< 0.001), while 12 
proteins were identified with high significance (0.001<p< 0.01). 
Table 2.5 Result List of T-Test from N-Glycosylation Sites Site-Specific Comparison 
 Protein N-linked Glycosylation Sites T-Test 
1 Alpha-1-antichymotrypsin TLJQSSDELQLSMGNAMFVK 4.25E-05 
2 Plasma protease C1 inhibitor VLSJNSDANLELINTWVAK 9.99E-05 
3 Alpha-1-acid glycoprotein 1 SVQEIQATFFYFTPJKTEDTIFLR 0.000179 
4 Carboxypeptidase B2 QVHFFVJASDVDNVK 0.003947 
5 Attractin DLDMFIJASK 0.004057 
6 Alpha-1-acid glycoprotein 1 SVQEIQATFFYFTPJK 0.004117 
7 Corticosteroid-binding globulin AQLLQGLGFJLTER 0.004803 
8 Ig alpha-1 chain C region LAGKPTHVJVSVVMAEVDGTCY 0.005974 
9 Protein Z-dependent protease inhibitor LPYQGJATMLVVLMEK 0.007457 
10 Adipocyte plasma membrane-associated protein AGPJGTLFVADAYK 0.007958 
11 Metalloproteinase inhibitor 1 FVGTPEVJQTTLYQR 0.007958 
12 Kininogen-1 ITYSIVQTJCSKENFLFLTPDCK 0.008506 
13 Serotransferrin CGLVPVLAENYJK 0.009305 
14 Alpha-1-antichymotrypsin FJLTETSEAEIHQSFQHLLR 0.009363 
15 Alpha-1-antitrypsin QLAHQSJSTNIFFSPVSIATAFAMLSLGTK 0.009572 
16 Kallistatin FLJDTMAVYEAK 0.01074 
17 Apolipoprotein(a) WEYCJLTR 0.010884 
18 Complement C4-A JTTCQDLQIEVTVK 0.011478 
19 Serum albumin JECFLQHKDDNPNLPR 0.012709 
20 Ceruloplasmin AGLQAFFQVQECJK 0.013654 
21 Complement factor B SPYYJVSDEISFHCYDGYTLR 0.014113 
22 Alpha-1B-glycoprotein EGDHEFLEVPEAQEDVEATFPVHQPGJYSCSYR 0.01421 
23 Hemopexin SWPAVGJCSSALR 0.0169 
24 Kininogen-1 HGIQYFNJNTQHSSLFMLNEVK 0.019126 
25 Haptoglobin MVSHHJLTTGATLINEQWLLTTAK 0.019152 
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26 Alpha-2-HS-glycoprotein KVCQDCPLLAPLJDTR 0.020809 
27 Clusterin QLEEFLJQSSPFYFWMNGDRIDSLLENDR 0.020994 
28 Inter-alpha-trypsin inhibitor heavy chain H4 LPTQJITFQTESSVAEQEAEFQSPK 0.021025 
29 Prostaglandin-H2 D-isomerase SVVAPATDGGLJLTSTFLR 0.021231 
30 Alpha-1-acid glycoprotein 1 NEEYJKSVQEIQATFFYFTPJKTEDTIFLR 0.021379 
31 Alpha-1-antichymotrypsin YTGJASALFILPDQDKMEEVEAMLLPETLK 0.025468 
32 Zinc-alpha-2-glycoprotein EDIFMETLKDIVEYYJDSJGSHVLQGR 0.027973 
33 Complement C4-A FSDGLESJSSTQFEVK 0.029349 
34 C4b-binding protein alpha chain LSVDKDQYVEPEJVTIQCDSGYGVVGPQSITCSGJR 0.03002 
35 Complement factor H SPYEMFGDEEVMCLNGJWTEPPQCK 0.03023 
36 Phospholipid transfer protein VSJVSCQASVSR 0.031654 
37 Ig mu chain C region GLTFQQJASSMCVPDQDTAIR 0.032091 
38 Ig gamma-4 chain C region TKPREEQFJSTYR 0.033035 
39 Ceruloplasmin ELHHLQEQJVSNAFLDK 0.035315 
40 Complement component C9 JETYQLFLSYSSK 0.036684 
41 Complement factor B ALQAVYSMMSWPDDVPPEGWJR 0.03774 
42 Alpha-1-antichymotrypsin YTGJASALFILPDQDK 0.038333 
43 Haptoglobin VVLHPJYSQVDIGLIK 0.038621 
44 Alpha-1-antitrypsin YLGJATAIFFLPDEGK 0.039556 
45 Fibronectin DQCIVDDITYNVJDTFHK 0.040001 
46 Complement component C7 INNDFNYEFYJSTWSYVK 0.040672 
47 Leucine-rich alpha-2-glycoprotein LPPGLLAJFTLLR 0.040706 
48 Clusterin QLEEFLJQSSPFYFWMNGDR 0.040827 
49 Apolipoprotein B-100 SSVITLNTNAELFJQSDIVAHLLSSSSSVIDALQYK 0.041787 
50 Complement factor H-related protein 3 LGYNAJTSILSFQAVCR 0.041948 
51 Complement factor H WDPEVJCSMAQIQLCPPPPQIPNSHJMTTTLNYR 0.044889 
52 Alpha-1-acid glycoprotein 1 QDQCIYJTTYLNVQR 0.047466 
53 Apolipoprotein B-100 LYQLQVPLLGVLDLSTNVYSNLYJWSASYSGGJTSTDHFSLR 0.048148 
 
Based on our statistical study, 53 proteins were reliable (p<0.05); among aforementioned 
information, 3 proteins were very highly significant (p< 0.001), and 19 proteins were identified 
with high significance (0.001<p< 0.01). Besides, 14 proteins had significant alternation on relative 
protein expression ratio. 
  30 
Table 2.6 Result List of T-Test from Protein Expression Comparison 
 Protein ID Protein Name T-Test 
1 P01011 Alpha-1-antichymotrypsin 0.000136 
2 P02748 Complement component C9 0.000595 
3 P02790 Hemopexin 0.000756 
4 P00751 Complement factor B 0.000991 
5 P01594 Ig kappa chain V-I region AU 0.001166 
6 P02042 Hemoglobin subunit delta 0.002181 
7 P01609 Ig kappa chain V-I region Scw 0.00239 
8 Q02985 Complement factor H-related protein 3 0.002495 
9 P0C0L5 Complement C4-B 0.002892 
10 P07360 Complement component C8 gamma chain 0.002995 
11 P0C0L4 Complement C4-A 0.003178 
12 P01607 Ig kappa chain V-I region Rei 0.003228 
13 P02751 Fibronectin 0.005603 
14 P01600 Ig kappa chain V-I region Hau 0.006406 
15 P80362 Ig kappa chain V-I region WAT 0.006406 
16 P01621 Ig kappa chain V-III region NG9 0.006585 
17 P02100 Hemoglobin subunit epsilon 0.007624 
18 P69891 Hemoglobin subunit gamma-1 0.007624 
19 P69892 Hemoglobin subunit gamma-2 0.007624 
20 Q04756 Hepatocyte growth factor activator 0.007624 
21 P01608 Ig kappa chain V-I region Roy 0.009575 
22 P08603 Complement factor H 0.010102 
23 P01610 Ig kappa chain V-I region WEA 0.012075 
24 P02735 Serum amyloid A-1 protein 0.013095 
25 P01834 Ig kappa chain C region 0.013605 
26 P00450 Ceruloplasmin 0.014054 
27 P04275 von Willebrand factor 0.014247 
28 P01871 Ig mu chain C region 0.015397 
29 P01599 Ig kappa chain V-I region Gal 0.01923 
30 P02766 Transthyretin 0.019293 
31 P01772 Ig heavy chain V-III region KOL 0.020374 
32 P80748 Ig lambda chain V-III region LOI 0.021085 
33 P04220 Ig mu heavy chain disease protein 0.021401 
34 P01023 Alpha-2-macroglobulin 0.02217 
35 P01764 Ig heavy chain V-III region 23 0.025756 
36 P01593 Ig kappa chain V-I region AG 0.028236 
37 P69905 Hemoglobin subunit alpha 0.028624 
38 P22891 Vitamin K-dependent protein Z 0.030239 
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39 Q6EMK4 Vasorin 0.030239 
40 P80108 Phosphatidylinositol-glycan-specific phospholipase D 0.031395 
41 P01009 Alpha-1-antitrypsin 0.035172 
42 P04003 C4b-binding protein alpha chain 0.036065 
43 P02654 Apolipoprotein C-I 0.03615 
44 P00738 Haptoglobin 0.036588 
45 P00739 Haptoglobin-related protein 0.036999 
46 P35908 Keratin, type II cytoskeletal 2 epidermal 0.037195 
47 P02538 Keratin, type II cytoskeletal 6A 0.037399 
48 P07357 Complement component C8 alpha chain 0.040112 
49 P05155 Plasma protease C1 inhibitor 0.040814 
50 P02652 Apolipoprotein A-II 0.044276 
51 P01031 Complement C5 0.044879 
52 P02760 Protein AMBP 0.046114 
53 P02787 Serotransferrin 0.04735 
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CHAPTER 3.  A STRUCTURAL ANALYSIS OF N-GLYCAN RELEASED FROM 
MONOCLONAL ANTIBODY USING HCD-MS/MS 
3.1 Introduction 
Immunoglobulins, also known as antibodies, is a group of Y-shaped glycoprotein serving 
as parts of the immune system to control infections caused by pathogens, like virus and bacterium, 
or allergens [59]. Several classes of immunoglobulin exist in human bodies, such as 
immunoglobulin A (IgA), immunoglobulin D (IgD), immunoglobulin E (IgE), immunoglobulin G 
(IgG), and immunoglobulin M (IgM). The genetic-caused or pathological immunoglobulin 
deficiencies develop or promote long-term (chronic) infections, for example, autoimmune diseases 
[60], allergies [61], or inflammatory diseases [62]. Therefore, IgG or other antibodies are 
successfully applied in disease diagnoses for the conditions mentioned earlier. Additionally, there 
are wide-spread medical applications, including disease therapy or prenatal therapy, with 
antibodies delivered via intravenous, subcutaneous, or intramuscular routes of administration; like 
insulin, proteins cannot be given through ingestion. Commercial mass production of antibodies, 
also called monoclonal antibodies (mAb) because of its generating method, is well-developed in 
methodology and technology. Several mAb products have been approved by FDA for cancers or 
autoimmune disorders treatments, such as adalimumab (brand name: Humira) from Abbott 
Laboratories.  
Glycosylation is one of the most common post-translational modifications (PTMs) of 
proteins and plays a significant role in the intercellular and intracellular communication processes 
[13]. According to research, the majority of serum proteins are believed to be glycosylated [12]. 
N-linked glycosylation not only increases the structural and functional diversity of the 
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glycoproteins but also serves as a criterion to monitor the activity of developmental stage and 
disease severity of a cell [14]. There is an association between many human diseases and the 
changes in the glycosylation of glycoproteins, such as cancer, cardiovascular disease, and immune 
deficiency diseases. Furthermore, some pathological influence on N-glycans of proteins, which 
contributes to the immune system, were proven to be related to the occurrence and development 
of many diseases, such as cancers [12, 17, 18], autoimmune disease [63, 64], and lymphocytic 
leukemia [65] or other diseases [19-21]. Additionally, glycans are highly regulated in the immune 
system, since glycans can perform as markers when any foreign infectious agents exist. Thus, the 
alternation of glycan structures is a pathogenic indicator for autoimmune diseases, such as 
rheumatoid and IgG immune complex to a diagnosis of rheumatoid arthritis [22]. Also, IgG is the 
smallest but most abundant immunoglobulin that offers the majority of antibody-based immunity 
in all humans [66]. It is engaged in several immune pathways, antibody dependent cell-mediated 
cytotoxicity (ADCC) and complement- dependent cytotoxicity (CDC), to fight against diseases 
like cancers [67, 68]. One conserved N-linked glycosylation site, Asn-297, is in the CH2 domain 
of the heavy chain (Fc fragments) with relatively high glycosylation occupancy. It is crucial to 
have the FC region glycan to support and control the immune reactions mentioned above. 
However, IgG glycosylation alters during disease or during different stages of life, which means 
that it is influenced by changes in age or pregnancy. Hence, the alteration of IgG glycosylation 
affects the binding of IgG to Fc receptors and C1q and further regulatory functions of IgG [23].  
There are two ways or levels to perform sugar structural analysis: glycan level or 
glycopeptides level. No matter which path is selected, isolation of glycan or glycopeptides can 
influence the coverage and discover the rate of possible sugar forms. Current progress in 
oligosaccharides and glycopeptides enrichments has shown that HILIC (hydrophilic interaction 
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chromatography) and affinity binding chromatography are the dominant methods utilized by 
research groups globally in order to increase glycopeptide signals in mass spectrometer [69, 70]. 
These two classes have several advantages over others: higher specificity and accuracy, high 
reproducibility and low affinity to non-target fragments. HILIC is the better among these two 
because of reasonable prices and simple operation [69]. Mapping the oligosaccharides at one or 
several specific glycosylation sites on a protein is a time-consuming procedure. However, 
analyzing glycopeptides in a single protein can obtain details for both heterogeneous glycan 
structures in targeting glycosylation sites and peptide containing glycosylation sites for sequence 
matching in one run. While there are several glycomics applications commercially available with 
reasonable accuracy; unfortunately, none of the software available includes functions to apply 
glycopeptide sequences into spectra mapping [71]. On the other hand, the software to analyze of 
intact glycopeptides with trustable accuracy has rarely been developed [72]. Additionally, HCD 
(higher-energy collision dissociation) is the main dissociation technique we applied in the analysis 
in glycopeptide level. Several advantages of HCD are qualified over CID. HCD offers more 
flexible collision energy that is proper for glycan analysis, since the bound of core-fucose is 
extremely sensitive to collision energy [73]. Further, CID has 1/3 cut-off effect during data-
acquiring process, while, HCD obtains a more comprehensive picture of all the fragments 
generated from sugar moiety, even when peptide bone is attached [74]. 
In our study, we gave a detailed description of glycan structural analysis on the level of 
glycopeptides with a comparison between SimGlyan software and manual deciphering. Tryptic 
glycopeptides from two assigned mAb were enriched with self-packed zwitterionic hydrophilic 
interaction chromatography (ZIC-HILIC) tip column and prepared samples ran HCD applied in 
nano-LC-MS-MS method. The raw files generated were mapped onto the peptide sequence, 
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allowing us to identify N-linked glycan through two approaches: manual mapping and SimGlycan 
application with peptide sequence as a modification. The results show that 19 and 23 N-glycan 
structures were determined from standard and modified mAb samples respectively by using 
SimGlycan software, while 38 and 35 glycan structures were recognized by manually mapping 
respectively. A total of 6 and 26 overlapped respectively from these two methods. 13 N-
glycoforms were identified with significant alterations by comparing standard sample (sample A) 
and modified mAb (sample B) by means of our method. Further, this method is a more affordable, 
feasible, and accurate technique for sugar structural studies from specific glycosylation sites with 
peptide sequence confirmation in one data collection cycle. It offers an approach for glycan 
structure study and also provides information to improve the currently available software. 
3.2 Materials and Experiments 
3.2.1 Materials and Chemicals 
Materials: monoclonal antibodies (mAb), including one standard (sample A) and one 
modified (sample B) samples, were supplied by National Institute of Standard and Technology 
(Gaithersburg, MD) with the amount of 400 µg respectively. 
Chemicals: Formic acid (FA), urea and ammonia bicarbonate solids were purchased from 
Sigma-Aldrich Co. (St. Louis, MO). ZIC-HILIC media was bought from Merck (Merck, 
Germany). Sequencing grade porcine trypsin and dithiothreitol (DTT) were obtained from 
Promega (Madison, WI); deionized water was produced by a Milli-Q A10 system from Millipore 
(Bedford, MA), YM-3(3kD) filtration devices were from the same company. Optimal LC-MS 
grade acetonitrile (ACN) and same grade water were acquired from Thermo Fisher Scientific, Inc. 
(Waltham, MA). 98% Iodoacetamide (IAA) was got from Alfa Aesar (Ward Hill, MA). 3M 
Empore C8 disk was bought from 3M Bioanalytical Technologies (St. Paul, MN).  
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3.2.2 Trypsin Digestion of Monoclonal Antibody 
Approximately 200 µg of each sample (2 µL) were included in following procedures 
according to the measurements on Nanodrop 2000 Spectrophotometer manufactured by Thermo 
Fisher Scientific, Inc. Incubate Buffer (8.0 M urea and 10mM DTT in 50mM ABC, pH 8.0) were 
added respectively to obtain the final concentration 4 µg/ µL. The units were incubated at 37 °C 
for three hours. Additional alkylating reagent (500 mM IAA in 50 mM ABC) was mixed finely 
with the samples with 50mM IAA as the final concentration, which was followed by a 30-minute 
alkylation under darkness at room temperature. Then, each system was combined with 1.2 µl 
reducing reagent (1M DTT in DI water) to react with any leftover alkylating reagent. 450 µl of 50 
mM ABC solution that contained 4 µg trypsin inside was added to each sample so as to dilute high 
concentration of urea. After being gently mixed on a vortex mixer, the sample systems were placed 
into 37 °C incubator for Over-Night (O/N) digestion. Treated peptides were dried under an 
Eppendorf Vacufuge Concentrator and stored in the -80°C refrigerator for future MS detection. 
3.2.3 Enrichment and Simplification of N-Glycopeptides Using HILIC Tips 
Roughly 100 µg of digested peptides were added into 25 mg ZIC-HILIC media and 
enriched by following the previously published procedures by Ma et al. [31]. The entire enrichment 
procedures were performed using a self-packed tip-size column. The detailed strategy is as 
follows: C8 extraction disk was tightly stuffed into a 200 µl pipet tip. Afterward, ZIC-HILIC media 
was suspended in 100 µl binding buffer (80% ACN, 5% FA) and injected into tips, and the systems 
were equilibrated with the same buffer twice. Digested peptides gently thawed were re-dissolved 
in the binding buffer and loaded into 200 µl prepacked tip with six times desalting and washing 
procedure with 100 µl binding buffer per round. Bounded glycopeptides were eluted twice with 
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100 µl elution buffer (99% H2O, 1% FA). The well-prepared samples were dried by a Vacufuge 
vacuum concentrator and stored in a refrigerator at -80 °C for further LC-MS/MS analysis. 
3.2.4 HCD – MS/MS Coupling with Nano-HPLC 
Reverse-phase nano-HPLC-MS/MS data were required from an LTQ-Orbitrap Elite mass 
spectrometer (Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 
high-performance liquid chromatography system (Thermo Fisher). EASY-Spray PepMap C18 
Columns were a separation unit with a length of 15 cm capillary filled with a C18 reversed phase 
resin (EASY-Spray Column PepMap C18; particle size, 2 µm; pore size, 100 Å; ThermoFisher). 
Separation was achieved by a mobile phase from 99.9% H2O, 0.1% FA (phase A) and 79.95% 
ACN, 19.95% H2O, 0.1% FA (phase B), and the linear gradient was from 5 to 40% buffer B for 
40 min at a flow rate of 300 nL/min. LTQ-Orbitrap Elite mass spectrometer was operated in the 
data-dependent mode. A full-scan survey MS experiment (m/z range from 400 to 1600; automatic 
gain control target, 1e6 ions; resolution at 400 m/z, 60,000; maximum ion accumulation time, 10 
ms) was acquired by the Orbitrap mass spectrometer, and ten most intense ions were fragmented 
by High-Energy Collision Dissociation (HCD) in the octopole collision cell. The HCD fragment 
ion spectra were acquired in the ion trap analyzer with the resolution of 15,000 at m/z 500 
(automatic gain control target, 1e4 ions; Default Charge State is 3; activation time, 0.5 ms). The 
MS2 scan model was set as the centroid. The other conditions used were: normalized collision 
energy is 27, charge state is ones larger than 1, and dynamic exclusion enabled in this method with 
1 repeat count, 18 repeat duration, exclusion duration is 30ms. Each sample was triplicated to 
analyze the stability and repeatability of the methods. 
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3.2.5 Data Annotation of N-Glycan from N-Glycopeptides Using SimGlycan 
The acquired MS/MS spectra from the instruments were submitted to SimGlycan 5.42 
(Premier Biosoft, Palo Alto, CA, USA) for database searching using an in-house, licensed 
SimGlycan server. The enzyme specificity was set to trypsin with two missed cleavages allowed. 
The peptide mass tolerance was set to 1.0 Da and MS/MS mass tolerance was set to 0.5 Da for the 
data analysis. Only scores for the peptides defined by the software greater than "identity" were 
considered significant for peptide identification and modification site determinations. The 
percentage of each glycoform for each specific core peptide was defined as the peak area for each 
specific glycoform/sum of the peak areas for all the glycoforms associated with the same core 
peptide. The peaks that related to peptides were pre-selected and used to provide predictions of 
potential compositions for the masses determined from MS/MS analysis. The precursor ion mass 
tolerance was set to 0.8 Da and tandem mass(MS/MS) tolerance was to 20 ppm initially and 
increased to 0.8 Da to increase the selectivity. Ion mode was positive, and the adduct was sedated 
carbohydrates. The resulting assignments were also validated manually if the assigned structure 
was not considered to be a possible component of the human glycoproteome (Xylose-containing 
glycans, inappropriately degraded structures, biosynthetic impossibilities). 
3.2.6 Manual Sugar Structural Determination from Data of N-Glycopeptides 
In this method, each raw data was manually selected for further glycan structural analysis, 
because 204 (HexNAc), 366 (HexHexNAc) or 290 (NeuGc-H2O) are the characteristic 
glycopeptide-marker ions in high-energy collision dissociation (HCD). Furthermore, ions at m/z 
186 and m/z 168 were generated from losing of one or two water molecules from the HexNAc 
oxonium ions [75, 76] can indicate for N-glycans existence [77]. The spectra of these individual 
ions were selectively chosen and summarized into another file, for example, EXCEL file, for 
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further analysis as well as the corresponding peak list. The peak lists were matched with the 
database at Consortium for Functional Glycomics (CFG) to narrow down the candidate pool. 
Furthermore, the potential structures were additionally selected and verified with 
GlycoWorkBench [78]. Another Database, glycosciences, was chosen as a resource. No 
derivatization or labeling agents was added. Since HCD was utilized as the primary technique, 
only B/Y ions were generated through tandem MS. Accuracy was set to 2.0 Dalton. The same 
procedures were re-performed for other 5 raw data files with the manual interpretation of results. 
3.2.7 Results Interpretation for Dominate Glycan Structure 
Theoretically, the candidate list required were accurate and reliable, peak areas for specific 
parent ion were obtained based on m/z and retention time. Following by merged six files together 
respectively into sample A and sample B subgroups. Abundance and standard deviation of each 
structure were calculated using the equation: specific peak area was divided by a sum of peak areas 
in one file. The calculation was performed in EXCEL utilizing built-in functions. 
 
Figure 3.1 The Workflow Scheme of Profiling Immunoglobulin N-Glycan Glycoforms 
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Spectra from both samples were recorded for three times under identical mass spectrometry 
condition. Further results were manually interpreted to generate a list of candidates. 
3.3 Results and Discussions 
3.3.1 N-Glycan Structural Profiling 
A schematic diagram of the N-linked glycan structural profiling is shown in Figure 3.1. 
The mass values in Dalton, in Figure 3.2, are utilized for glycan structure determination. These 
building blocks have identical molecular weights as the neutral lost fragments that collide off the 
non-reducing end of glycan in the mass spectrometer.  
 
Figure 3.2 The Mass Values in Daltons Used in Glycan Structure Interpretation 
3.3.2 Results Analysis with Data Generated from SA and MI Approaches 
 In our study, a total of 19 glycan sugar structures was identified from standard sample A 
and 23 glycoforms were discovered in sample B, which is designated as unknown, from software 
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searching including 6 identical structures. On the other manual interpretation strategy, a total of 
38 and 35 structures were identified from both sample respectively with 26 overlapping, 
meanwhile confirming with other published researches [79]; 6 structures are novel structures that 
haven’t been reported [79]. The structures determined by SimGlycan were contained in the list 
generated through manual interpretation strategy. The complete list of identified structures from 
standard (sample mAb-A) was listed in the supplement materials. Among these, two results from 
these samples share 15 glycan structures including 13 with significant differences in Figure 3.4. In 
the meanwhile, standard deviations were considered and labeled in Figure 3.5 to show the potential 
differences. For sample B (modified mAb), Table 3.2 lists the identified structures. Since NIST 
didn’t offer any biological or structural information regarding these samples, we only can predict 
the possible kinetics and dynamics on the basis of literature studies on sugar structures. 
 
 
Figure 3.3 The Comparison between Two Results from SA and MI 
By comparing two methods together, manual interpretation (MI) approach has approximate 1.5-
fold higher identification number compared to SimGlycan software analysis (SA) method. The 
overlapping discovery comparison ratio between two techniques – SA to MI – is over 4 times. 
3.3.3 Initial Results Interpretation from SimGlycan 
Initially, a total of 25 and 44 glycan structures were identified from sample A and B 
respectively without sharing glycoforms, which caused our assumptions. Under further analysis, 
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some structures identified were irrational, for example, xylose broadly exists in bacteria or fungi 
in nature, and none has been determined in mammals [2]. On a basis of literature suggestions, the 
candidates – includes xylose, etc. were eliminated from our list. Additionally, filtered sequences 
were optimized and verified with published known structures resulting fewer reasonable 
identifications – 21 from A and 27 from B. The full set of results was matched with manual 
interpretation results with full inclusion. Based on this reason, only the first set of data was run by 
SimGlycan on a basis of low identification accuracy.  
 
 
Figure 3.4 Glycan Structures with Significant Variations that Identified from MI 
A total of 26 glycan structures overlapped between sample A and sample B by using manual 
interpretation strategy. Among those, 13 out of 26 glycans showed a significant difference, the 
first 6 structures were hyper-expressed in sample A, while, the other 7 showed a decrease between 
these two. 
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Figure 3.5 Carbohydrate Structural Comparison between Sample A and B 
Carbohydrate forms with error bars were displayed in this figure. G0 structure (#1 in the list) is 
the most dominate glycoform. Several structures are with mild alternation between these two 
samples. 
3.3.4 A Comprehensive Explanation of MI Approach’s Procedures 
Without the invention of accurate and precise searching engineers, the current optimal 
strategy is to interpret manually spectra that are potentially from target glycopeptides. Regarding 
the preciousness of two samples, there was a set of experimental studies conducted with identical 
specimens, which is donated from Dr. Liu’ lab at Augusta State University. During the 
experimental practices, 100 ug of mAb was utilized to imitate the entire process; meantime, a 
glycopeptide list was generated accordingly to include all the miscleavage conditions. The 
detectable glycopeptides sequences – contains Asn 297– are EEQYNSTYR (MW: 1189.512 
Daltons) and TKPREEQYNSTYR (MW:1671.8085 Daltons) with double charges. The formation 
of glycopeptides is accomplished by transferring of precursor oligosaccharides to polypeptides in 
the lumen of the endoplasmic reticulum (ER) membrane through an enzymatic reaction. 
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Oligosaccharyltransferase is the enzyme responsible for the transfer of the precursor glycan to an 
asparagine residue in polysaccharide acceptor and generation of 1 water molecule. There are 
several criteria for this specific N-glycosylation site, asparagine, to satisfy before the glycan 
transfer stated above:  
1) Asn must follow the consensus sequence in Asn-X-Ser/Thr (X is not Pro). 
2) Asn should locate on the surface of the fully folded protein acceptor. 
3) Asn must be acceptable on the luminal side of the ER membrane for precursor oligosaccharides 
transfer [80]. 
Based on those principles, the entire MS2 spectra interpretation procedures were described 
in the following diagram (Figure 3.6). In the MS/MS spectrum, the target peptide was 
TKPREEQYNSTYR with one miscleavage at second amino acid, lysine (K). The peak 
(M/Z=937.95, Z=2) was the above peptide with one HexNAc; theoretically, N-glycopeptides is 
more likely to lose the entire sugar chain except the first HexNAc [81]. The differences between 
each peak were interpreted as double charged monosaccharides – monosaccharide molecular 
weight is shown in Figure 3.6 on the right. Moreover, the oligosaccharide chain is deduced through 
the molecular weight difference as N-glycan sugar core with two HexNAcs and one Hex. 
Additionally, this MS2 spectrum was fragmented from a precursor ion, M/Z 1093.80, and the 
charge state is 3 in this spectrum. Therefore, the glycopeptides molecular weight is the mass of 
both precursor oligosaccharides and polypeptides acceptor with losing one water molecule, then 
the molecular weight of this glycopeptide was calculated by hand, which is 3299.4 Daltons. The 
glycan sequence mass was drawn on the basis of these calculations, 1627.5915 with a hydrogen 
ion. The sugar information was analyzed and confirmed with glycan database Consortium for 
Functional Glycomics (CFG). Lastly, the sugar chain structure was proved as shown in Figure 3.6. 
  45 
This strategy is capable of deducing the glycan structure with the knowledge of protein 
sequence. Without information about protein backbone, it would be extremely tough to decipher 
N-linked glycan structures. N-glycosylation sites are easier to verify and speculate by following 
the criteria described above. Preferably proteins including one N-glycosylation site, the mAbs in 
this study, is more practical compared to proteins with multiple N-glycosylation sites.  
 
Figure 3.6 An Example of MI Interpretation 
One spectrum was selected to explain the interpretation of oligosaccharide structure (on the left), 
each peak was marked with its theoretical glycopeptides structure. Meanwhile, the glycopeptide 
structure was determined as the diagram in the corner. The list on the right is a molecular mass of 
monosaccharide component in N-glycan structures. 
3.3.5 Discussions and Suggestions in Choosing between MI and SA Methods 
Simglycan, developed and designed by a tech company called Premier Biosoft, is one of 
high throughput glycan and glycopeptide identification software which is widely used around the 
world. On the basis of the MS/MS and multi-stage mass spectrometry (MSn) data, SimGlycan 
predicts structures of glycans, however, the software is not easy to operate and requiring high 
expertise in glycomics. However, technology service offered from the company can offset these 
drawbacks. On the other aspect, SimGlycan functions under a strong dependence with the currently 
published database. Therefore, SimGlycan is not optimal for novel glycan structure determination. 
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Even though the updated database is continually offered and uploaded to their website, it requires 
a valid annual membership to access these information packages. For the institutions or industries 
have no intention to pursue in-depth understanding in glycomisc, they are reluctant to invest their 
profits into software that they only need for once.  
Table 3.1 The Brief Analysis of Advantages and Disadvantages between These Two 
Techniques.  
 SimGlycan Manual Interpretation 
Price $ 10,000 per year < $ 100 
Accuracy Depends on database Depends on researcher expertise 
Number of Identification 
(total) 
25 for A, 44 for B 38 for A, 35 for B 
Number of Identification 
(verified) 
19 for A, 23 for B 38 for A, 35 for B 
Time consumption (same 
spectra) 
Hours (up to 24 hrs) Days (at least 1-2 days) 
Easy to operate Hard Easy 
Database Dependence High Low 
Consistency of Result Output Low High 
Before deciding the strategy to persist on, researchers are suggested to consider these factors so as 
to make a deliberate choice. 
By comparing our MI results with the ones generated by SimGlycan, approximate 30 
percent of their identifications are false or misleading because of xylose’s existence; however, the 
results generated from manual interpretation technique were verified with several database and 
literature that the false identification rate (FDR) is limited less than five percent. Secondly, the 
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identification consistency in SimGlycan is not acceptable with a standard deviation higher than 
10.   
Despite these disadvantages of SimGlycan, software involved data interpretation process 
is time-saving and efficient when a large number of data or complicated glycoproteins (more than 
5 N-linked glycosylation sites) are involved in the researches. Researchers need to consider those 
facts before determining the techniques they will persist on. 
3.3.6 The Influences of Different Glycoforms on Monoclonal Antibody During in 
vivo Distributions 
Currently, there are approximately 40 therapeutic monoclonal antibodies approved by the 
Food and Drug Administration (FDA), and the number is rapidly increasing annually. Most of 
these approved mAbs are the treatments for cancer, autoimmune disorders or infectious diseases 
despite the reacting mechanisms. In the meantime, pharmaceutical companies are thriving in 
engineering novel monoclonal antibodies with traditional cancer treatments attaching, such as 
radioummunotherapy (mAbs carrying radioactive materials), chemoimmunotherapy (mAbs bind 
with cancer- targeting chemical) or immunoliposome therapy (mAbs attaching with liposome 
contains drugs or so) [82]. Further explorations are carrying out and gaining satisfactory 
achievements; bispecific antibodies, a new class of therapeutic antibodies structurally and 
functionally merging two monoclonal antibodies, is one of the novel engineered products and 
under clinical trials currently [83]. N-glycans on position Asn 297 in monoclonal antibodies serve 
not only crucial structural functions but also affects mAbs behaviors in a human body. The terminal 
sugars influence the half times of mAb confirmed in mice model and healthy volunteers. Sialic 
acid has a potential to increase the retention time in circulation; the removal of terminal galactose 
serves a significant function to prolong half-life as well [84, 85]. Additionally, galactose is the 
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most variable residue of the Fc sugar core by nature; it alternates relying on age. IgG is less 
galactosylated when people are in their childhood or elder [86]. However, monoclonal antibody 
with G0 structure (sugar core with two GlcNAc), which derived from the marine source, induces 
a potent antibody-dependent cell cytotoxicity even though G0 naturally exist in the human body 
[86]. Furthermore, modified mAb with high-mannose glycan indicates faster serum clearance in 
Goetze et al.’s research [87]. 
In this study, sample A and B were determined significant differences in 13 glycan 
structures; however, any information for these two samples are confidential that NIST was not 
willing to offer. Like this, we made our assumptions on a basis of limited sample information. In 
Figure 3.5, G0 structure was the most dominant structure in both samples, notwithstanding, G0 in 
sample A is significantly higher than in sample B. On the basis of the sample resource, mammal, 
we can make following assumptions: 1. The samples can naturally generate by a human, that these 
donors should be either young or senior. A lot of evidence has been showing that aging can trigger 
the elimination of terminal galactose in immunoglobulin G that generated in a human [64, 88, 89]. 
2. Both mAbs doesn’t have a long circulation and can trigger ADCC in treatments because of the 
lacking of terminal sialic acid [90]. 3. Modified mAbs (B) may treat with some enzyme or stored 
in a different environment, compared with standard mAb (A). The unsuitable environment may 
cause the degradation of sugars and proteins. However, we have to confirm with NIST after the 
entire study finished.  
3.4 Conclusions 
In this study, we measured and compared two glycomics strategies, SimGlyan software, 
and manual deciphering, and gave a detailed description of glycan structural analysis on the level 
of glycopeptides. The results were showing that glycoform manual interpretation offers over 50 % 
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more sugar structure in total identification numbers and determines more reliable results. A total 
of 13 N-glycoforms were identified with significant alterations by comparing standard sample 
(sample A) and modified mAb (sample B) by means of MI technique. Further, this method is a 
more affordable, feasible, and accurate technique for sugar structural studies from specific 
glycosylation sites with peptide sequence confirmation in one data collection cycle. However, MI 
strategy is time- and man power-consuming, additionally it required adequate knowledge in 
glycoscience to decipher the structures. In the meantime, current commercially available software 
is continuously improving, and our method offers an approach for glycan structure study and also 
provides information to improve the current software. 
3.5 Complementary Materials 
3.5.1 The Glycan Structures Identified in Standard (A) and Modified Standard (B) 
Table 3.2 The List of Glycan Structures Identified from A and B 
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The “x” symbol marks the existences of the structures identified from sample A and B. 45 
structures were identified in total, and a total of 26 structures were overlapped between these two 
samples. A sum of 15 structures was shown the significant differences (p-value< 0.05). 
3.5.2 Raw Data of the Glycan Structures with Significant Differences between A and 
B 
Table 3.3 Raw Data for These 15 Glycoforms that Shown Significant Differences Among 
Samples 
A sum of 13, out of 15 structures, indicated more significant alterations as displayed in Figure 3.4. 
The MeV figure revealed the variations between these samples. 
RAW DATA: GLYCAN QUANTIFICATION 
 
Replicates of Sample A, % 
Abundance 
Replicates of Sample B, % 
Abundance 
CFG 
Structure 
Replicate 1 Replicate 2 Replicate 3 Replicate 1 Replicate 2 Replicate 3 
 
81.945326 82.937990 80.992415 78.712660 72.264833 79.343492 
 
2.8594026 2.6074288 3.8819953 1.1898828 1.4747874 1.8616107 
 
0.0476739 0.0506948 0.0586817 0.1144515 0.2341295 0.2303661 
 
8.8705747 8.7763842 9.406874 11.863913 11.251477 11.273944 
 
0.0476322 0.0498587 0.0403742 0.0408146 0.1326709 0.0832415 
 
0.0307472 0.0339171 0.0458920 0.0575719 0.0645593 0.0576141 
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0.0601871 0.0538477 0.0538320 0.2308331 0.2406265 0.2384165 
 
0.2782378 0.2082737 0.2330320 0.8607019 0.8368441 0.3241289 
 
0.3380569 0.2737635 0.3158677 0.0756593 0.0634435 0.2224489 
 
0.2376010 0.2499111 0.2370788 0.0381455 0.0350103 0.1871761 
 
0.0668847 0.0669907 0.0637572 0.0266094 0.0352314 0.0102329 
 
1.5837620 1.0481779 1.6669027 0.0184304 0.0661279 0.0763673 
 
2.3408574 1.0233581 1.8472980 1.2361462 1.8170845 2.5856241 
 
0.0764650 0.0393770 0.0643994 0.0527350 0.0343951 0.0363303 
 
0.0711352 0.0703319 0.0795941 0.1403469 0.1494302 0.1669990 
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CHAPTER 4.  A COMPREHENSIVE STUDY OF MODIFIED HEMAGGLUTININ 
FROM PROTEOMICS AND GLYCOPROTEOMICS ASPECTS 
4.1 Hemagglutinin Proteinaceous Sequence Mapping 
4.1.1 Introduction 
Influenza virus, broadly known as “Flu virus”, can cause a contagious disease, influenza, 
among human, avian, or porcine [91]. Usually, the virus is spread through coughing or sneezing 
into the air. The virus can circulate worldwide and infect several individuals in any age group 
seasonally [92]. The influenza virus has a higher potential and frequency to mutate, which is an 
extraordinary threat to the human population; for example, the flu outbreak in China in 2009 and 
the pandemics spreading in the United States (U.S.) in 1957. The influenza viruses,, includes 
influenza virus A, influenza virus B and influenza virus C, were a type of RNA viruses that were 
included in Orthomyxoviridae family according to virus classification [93]. The type A influenza 
virus is the most common and widespread among these three subtypes. However, influenza A 
viruses are divided into several subtypes based on two glycoproteins, Hemagglutinin (HA) and 
neuraminidase (NA), located on the surface of the virus. HA is vital for influenza virus to attack 
and blend in with host cells. In more detail, HA recognizes target host cells through sialic acid 
ligand on host cells’ surfaces, usually in the upper respiratory tract or erythrocytes, and forms an 
endosome with enveloped virus. When pH drops, HA rearranges the structure and releases 
endosome, which contains viral internal RNA genome, into the cytoplasm of the host. 
HA and NA are the only two glycoproteins, proteins with N-linked glycosylation sites, 
which exists on the influenza virus. Due to the evolution of the immune system, the capabilities of 
these glycoproteins alternate to react against existing vaccines when infections continuously 
appear through a pandemic era [91]. Meanwhile, the classification of influenza type A utilizes 
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these antigenic variations that are divided into 16 subtypes of HA and a total of 9 NAs. The 
nomenclature of influenza type A is based on these HA and NA subtypes. During the antigenic 
alternations, amino acid sequence modifies near receptor-binding sites in HA and consequently 
influence the specificity and affinity of viruses and host cells. Theoretically, N-linked 
glycosylation sites generally follow the [N-X-S/T] sequence motif (sequon) in which X denotes 
any amino acid except proline [94]. Besides, there is no evidence showing any O-linked 
glycosylation observed among these protein subtypes [95]. Hence, glycosylation of HA and NA 
can affect the host specificity, virulence and infectivity of an influenza strain either directly, by 
changing the biological properties of HA and NA; or indirectly, by attenuating receptor binding, 
masking antigenic regions of the protein, regulating catalytic activity or preventing proteolytic 
cleavage of the stalk of NA. Paulson’ group demonstrates that certain subtypes of HA in influenza 
has higher capability to bind sialic acids selectively in a2-6 linkage, which primarily exists in the 
human respiratory track [96].  
Currently, vaccination is the most efficient method to prevent seasonal influenza infections 
other than avoiding any contact with patients [97]. However, the rapid mutation and drug 
resistance of these viruses urge scientists to predict potential flu strains and to engineer the suitable 
vaccines. The number and distribution of the N-glycosylation sites over the viral proteome can be 
computationally studied and theoretically predicted by scanning the sequences for these sequons. 
Therefore, the combination of computational prediction and virological engineering is timely 
essential for forecasting and preventing the outbreak of a new influenza virus mutant before a 
pandemic outbreak. 
In this chapter, the major focus is on protein sequence verification of hemagglutinin 
influenza and N-glycosylation site identifications in these hemagglutinin isomers. The coverage 
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of each protein under trypsin digestion treatment is over 90% by utilizing our techniques. 
Furthermore, 5 out of 5 glycosylation sites in both hemagglutinins were identified and verified 
through our two-enzyme methods. There is an additional analysis of glycosylation occupancy for 
each glycosylation sites, which varies from site to site. The technique described in this chapter 
established a method that can be widely applied to any protein or glycoprotein analysis. 
4.1.2 Materials and Experiments 
4.1.2.1 Materials and Chemicals 
Sequencing grade porcine trypsin and sequencing grade Endoproteinase GluC were 
purchased from Promega (Madison, WI); formic acid (FA) liquid, heavy-label H218O water, urea, 
and ammonia bicarbonate solids were obtained from Sigma-Aldrich Co (St. Louis, MO). Peptide-
N-glycosidase F (N-glycanase F, PNGase F) was purchased from New England BioLabs (Ipswich, 
MA). The YM-30 (30 kD) and YM-3(3kD) filtration devices were purchased from Millipore 
(Bedford, MA), deionized water was produced by a Milli-Q A10 system from the same company. 
Optimal LC-MS grade quality acetonitrile (ACN) and same grade quality water were purchased 
from Thermo Fisher Scientific, Inc. (Waltham, MA). Dithiothreitol (DTT) was obtained from 
Promega, and 98% 2-Iodoacetamide (IAA) was acquired from Alfa Aesar (Ward Hill, MA). HA1 
and HA2 purified protein stored in phosphate buffered saline (PBS) were generously donated by 
our collaborator. 
4.1.2.2 Desalting Procedures 
Approximately 200 µg of each sample (sample volume around 100 µL) were included in 
following procedures according to the measurements on Nanodrop 2000 Spectrophotometer 
manufactured by Thermo Fisher Scientific, Inc. The samples were loaded into 3KD Microcon 
  55 
filtration devices for buffer changing. The units were centrifuged to the dead volume under 14000g 
centrifugation at 4oC. 100 µL of 50 mM ammonium bicarbonate were genteelly mixed with protein 
pellet and centrifuged for 15 minutes under 14000g centrifugation at 4oC. In order to reach the 
optimal buffer condition, this buffer exchange step was repeated for 6 times.  
4.1.2.3 Filter-Aided Sample Preparation with Trypsin (FASP-T) 
The system was combined with 80 µl Incubate Buffer (8.0 M urea and 10mM DTT in 
50mM ABC, pH 8.0), and incubated at 37 °C for three hours. 200 µl of Urea solution (8 M urea in 
0.1 M Tris/HCl, pH 8.5) was combined with protein solution before 1 hour of 14000g 
centrifugation at room temperature. 100 µl of Urea solution was deposited into each filter unit and 
resumed centrifuged for 10 minutes continuously two times. Followed by another centrifugation 
step, the concentrates were combined with 100 µl of 50 mM IAA in Urea solution, and the units 
were incubated in darkness at room temperature for 30 minutes. After twice of Urea solution 
addition/centrifugation process, the systems were equilibrated twice with 100 µl of 50 mM 
ammonia bicarbonate (Elution Buffer) and centrifuged until the dead volume inside the filter was 
less than 20 µl. 100 µL Elution Buffer was added to each filter unit, followed by adding 2 µg 
trypsin. Digestion conditions were under process at 37 °C O/N. In order to elute desired tryptic 
peptides entirely, the filter units (applicable to both methods) were rinsed with 100 µl elution buffer 
under centrifugation for five times. Collected flow-through peptides were dried under Eppendorf 
Vacufuge Concentrator and stored in the -80°C refrigerator for future sugar release procedure. 
4.1.2.4 In-Solution Digestion with Trypsin (ISD-T) 
The unit from desalting procedure was removed by 50% ACN in 50mM ABC with the 
filter upside down. The protein mixture proceeded to further preparation methods as following. 
Incubate Buffer (8.0 M urea and 10inmM DTT in 50mM ABC, pH 8.0) were added respectively 
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to occur 50µL as the final volume L. The units were incubated under 37 °C for three hours. 
Additional alkylating reagent (500 mM IAA in 50 mM ABC) was mixed finely with the samples 
with 50mM IAA as final concentration, which followed by 30-minute alkylation under darkness 
in room temperature. Then, each system was combined with 1.2 µl reducing reagent (1M DTT in 
DI water) to react with any leftover alkylating reagent. 450 µl of 50 mM ABC solution that 
contained 4 µg trypsin inside was added to each sample so as to dilute high concentration of urea. 
After gently mixed on a vortex mixer, the sample systems were placed into 37 °C incubator for 
O/N digestion. Further, the units were incubated for 5 minutes at 95°C to denature trypsin. Treated 
peptides were dried under Eppendorf Vacufuge Concentrator and stored in the -80°C refrigerator 
for further preparations. 
4.1.2.5 Enzymatic Deglycosylation in Peptide Preparation 
The pellets were reconstituted in 50 µL G7 buffer (50 mM Sodium Phosphate, pH 7.5) and 
incubated with peptide-N-glycosidase F (N-glycanase F, PNGase F) for 12 hours under 37 °C for 
deeper digestion following the published procedure previously [98]. The samples were dried in a 
vacuum concentrator and stored in a refrigerator at -80 °C for LC-MS/MS analysis. 
4.1.2.6 Nano-LC-MS/MS Peptide-Mass Fingerprinting (PMF) 
Reverse-phase nano-HPLC-MS/MS data were required from an LTQ-Orbitrap Elite mass 
spectrometer (Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 
high-performance liquid chromatography system (Thermo Fisher). EASY-Spray PepMap C18 
Columns were a separation unit with a length of 15 cm capillary filled with a C18 reversed phase 
resin (EASY-Spray Column PepMap C18; particle size, 2 µm; pore size, 100 Å; ThermoFisher). 
Separation was achieved by a mobile phase from 99.9% H2O, 0.1% FA (phase A) and 79.95% 
ACN, 19.95% H2O, 0.1% FA (phase B), and the linear gradient was from 5 to 40% buffer B for 
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40 min at a flow rate of 300 nL/min. LTQ-Orbitrap Elite mass spectrometer was operated in the 
data-dependent mode. A full-scan survey MS experiment (m/z range from 400 to 1600; automatic 
gain control target, 1e6 ions; resolution at 400 m/z, 60,000; maximum ion accumulation time, 10 
ms) was acquired by the Orbitrap mass spectrometer, and ten most intense ions were fragmented 
by High-Energy Collision Dissociation (HCD) in the octopole collision cell. The HCD fragment 
ion spectra were acquired in the ion trap analyzer with the resolution of 15,000 at m/z 500 
(automatic gain control target, 1e4 ions; Default Charge State is 3; activation time, 0.5 ms). The 
MS2 scan model was set as the centroid. The other conditions used were: normalized collision 
energy is 27, charge state is ones except 1, and dynamic exclusion enabled in this method with 1 
repeat count, 18 repeat duration, exclusion duration is 30ms. The full process description is 
attached in the supplement. Each sample was triplicated to analyze the stability and repeatability 
of the methods. 
4.1.2.7 The Confirmation of the HA-1 and -2’s Coverages Using Designated Databases 
This procedure has followed a publication from Dr. Ma [31] with some minor modification 
to reach the high results. The raw data were searched though pFind 2.1 in HA-1 and HA-2 protein 
database and its reverse sequences. The modifications were optimized: the static modification is 
Carbamidomethyl (Cys), and the dynamic modifications were generic: Deamination (Asn), 
Oxidation (Met) and Gln to pyro-Glu (Any N- terminal started with Q). The most significant 
modification is a 0.9840 Da m/z difference when Asn altered into Asp. Trypsin was selected as 
the enzyme, and two missed cleavages were allowed. The mass tolerance of the precursor ion was 
set to 20 ppm and the fragment ions mass tolerance was 0.8 Da. A false discovery rate (FDR) of 
1% was estimated and applied to all data sets at the total peptide level. Further, the pBuild was 
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used to remove redundant protein entries and to group related proteins into a single group entry 
with the coverage information as well. 
4.1.3 Results and Discussions 
4.1.3.1 The Coverage Determination of HA-1 and HA-2’s Sequences through PMF 
A schematic diagram of the protein coverage determination for both proteins are shown in 
Figure 4.1.  
 
Figure 4.1 The Workflow of Protein Sequence Coverage Determination 
Two techniques were applied into protein digestion, in-solution digestion and FASP, to obtain 
better coverages. The same techniques were used to both proteins. 
Two samples were respectively performed under the workflow shown Figure 4.1 in order 
to obtain the essential and reliable data. Two purified HAs when received were performed using 
in-solution or filter-aided sample preparation (FASP) digestion with trypsin. Tryptic peptides, after 
digestion, were further analyzed with a high-precision Orbitrap Elite. All the spectra were 
confirmed with fasta files, attached to supplement material, through pFind software. Obtained 
peptide mass fingerprinting mapping information was generated with peptides molecular weight 
and coverages. The coverage results are attached in Figure 4.2.   
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4.1.3.2 FASP Technique Gives Better Coverage of Sequences than IS Digestion Method 
Based on our result in Figure 4.2, FASP method has more comprehensive peptide sequence 
coverage, 90.94% for HA-1 and 69.18% for HA-2, over in-solution (IS) technique, 73.40% and 
40.38% respectively for HA-1 and HA-2. There are several reasons to explain the superiority of 
FASP strategy. FASP method involves several spin wash processes after adding each reacting 
reagent, which can effectively remove detergents or salts, such as SDS or phosphate salt, to prevent 
contaminations in the mass spectrometer. However, in solution digestion is conducted under small 
volume enzyme-preferred buffer, which frequently contains Tris or ammonium bicarbonate. Since 
protein preserves in specific buffer contain SDS or glycerol, these compounds can increase noise 
signal and analysis difficulty in mass spectrometer detection and suppress proteolytic digestion by 
deactivating enzymes.   
 
Figure 4.2 A Fully Comparisons between FASP and IS Strategies.  
The results of HA-1 and -2 from FASP method are on the left and results from IS technique are on 
the right side. According to our results, FASP method has better peptide mapping coverage and 
excellent confirmation ratio of n- linked glycosylation sites. However, in solution digestion 
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method was still adopted in further analysis to confirm our assumption and increase the reliability 
of our initial results. 
4.1.3.3 Trypsin is More Capable for HA-1 PMF than HA-2 in Protein Digestion Level 
HA-1 and HA-2 are two analogs of the glycoprotein, hemagglutinin, with artificial 
modifications. HA-1’s molecular weight is 58895.26 Daltons, while HA-2 molecular weight is 
63867.97 Daltons. The sequences of both proteins were identical for the first 530 amino acids 
besides 41 additional peptides, containing one polyhistidine tag (6 histidines) at C-terminal, in 
HA-2, alignment of both proteins was included in Figure 4.3. Two proteins were performed 
simultaneously under the same procedures avoiding man-made errors. The protein coverage for 
both proteins was surprisingly different: The coverage of HA-1 after trypsin digestion is 89.43%. 
However, HA-2 has a lower coverage of 69.18% as described (Figure 4.2).  
A purification technique that involved polyhistidine affinity tags (usually contains 6-9 
histidines) to interact with metal ions is widely utilized in target protein purifications. Generally, 
the affinity tags retain on targeted protein after purification process without being removed, 
because the placement of the tag is optimized specifically for the target protein [99]. However, 
immobilized metal-affinity chromatography (IMAC) is selectively efficient to enrich tagged 
protein expressed at relatively higher expression rate – higher than the naturally expressed protein 
with the his-tag. Thus, failure of placing his-tag into the optimal position may lower the enrichment 
of target protein. One of these assumptions is that the last 41 amino acids may form a shield to 
protect tryptic cleaving positions, lysine (K) and arginine (R); additionally, the cleavages of HA-
1 and HA-2, especially the last 41 amino acids, the interval between each K or R is too compact 
to support the ability of trypsin. The spatial structure of glycan attached is generally quite large 
and could potentially block trypsin to access these two residues as well. Furthermore, IMAC 
technique is not compatible with chemical protease inhibitors, like EDTA or DTT, since these 
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compounds may weaken the affinity from nickel ions. Therefore, protease inhibitor cocktails are 
intended to add into cell lysate to sustain degradation and deactivation of aimed proteins [100]. 
Thus, this is one of these assumptions that HA-2 sample contains or failed to remove these protease 
inhibitors through desalting procedures (dialysis) and further hinders trypsin cleaving activity. The 
addition of protease inhibitors influenced HA-2 coverage. 
4.2 Multi-Enzyme Digestion to Improve Proteinaceous Coverages for HA-1 and -2 
4.2.1 Introduction 
Trypsin is one of the most widely applicable proteases in the sample preparation for 
proteomics study which cleaves specifically at arginine (Arg/R) and lysine (Lys/K) [101]. 
However, it is not the most suitable enzyme in post-translational modifications since the attached 
carbohydrates sterically hinder the cleavage sites away from trypsin. Thus, miscleavages have 
frequently occurred in glycoprotein studies [50]. Further, trypsin is not absolutely optimal to some 
glycoproteins because of missing cleaving sites, Arg and/or Lys. For overcoming the limitations, 
proteases, such as pronase [102] or proteinase K [103] have been accepted for glycoprotein 
matabolism in nonspecific manners. Some other enzymes are applied into glycoprotein digestion 
to overcome the shortage of Arg and/or Lys in protein sequences, such as endoproteinase Glu-C 
[104]. The smaller size of digested peptides increases not only detection signals and resolution in 
mass spectrometer data collecting process, but also improves sequence coverage by analyzing 
peptides generated in multiple enzymes treatments [50].  
In this part of the dissertation, more comprehensive sequence coverage of HA-1 and -2 are 
identified in over 85% respectively, compared to single-enzyme digestion, trypsin. Further, we 
confirmed the importance of changing protein preserved buffer, phosphate buffered saline (PBS), 
into ammonia bicarbonate (ABC) buffer to retain enzyme activities. 
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Figure 4.3 The Sequence Alignments between HA-1 and HA-2 
The alignment results from T-Coffee are shown that HA-1 and HA-2 are 100% matched besides 
the last 41 amino acids from HA-2.  
4.2.2 Materials and Experiments 
4.2.2.1 Materials and Chemicals 
All the materials and chemicals are identical with section 4.1.2.1. 
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4.2.2.2 Filter-Added Sample Preparation with Trypsin & Glu-C (FASP-T&GC) 
The system was combined with 80 µl Incubate Buffer (8.0 M urea and 10mM DTT in 
50mM ABC, pH 8.0), and incubated at 37 °C for three hours. 200 µl of Urea solution (8 M urea in 
0.1 M Tris/HCl, pH 8.5) was combined with protein solution before 1 hour of 14000g 
centrifugation at room temperature. 100 µl of Urea solution was deposited into each filter unit and 
resumed centrifuged for 10-minute continuously two times. Followed by another centrifugation 
step, the concentrates were combined with 100 µl of 50 mM IAA in Urea solution, and the units 
were incubated in darkness at room temperature for 30 minutes. After twice of Urea solution 
addition/centrifugation process, the systems were equilibrated twice with 100 µl of 50 mM 
ammonia bicarbonate (Elution Buffer) and centrifuged until the dead volume inside the filter was 
less than 20 µl. 100 µL of 50mM ammonium bicarbonate with Glu-C enzyme (enzyme: protein 
ratio is 1:100) added to the unit at 37 °C incubation overnight. Trypsin stock solution (enzyme: 
protein ratio is 1:25) was mixed with the solution in the unit; the system was incubated under 37 
°C for the same period. Digestion conditions were under process at 37 °C overnight. In order to 
elute desired tryptic peptides entirely, the filter units (applicable to both methods) were rinsed with 
100 µl elution buffer under centrifugation for five times. Collected flow-through peptides were 
dried under Eppendorf Vacufuge Concentrator and stored in the -80°C refrigerator for future sugar 
release procedure. 
4.2.2.3 In-Solution Digestion with Trypsin &Glu-C (IS-T&GC) 
The unit from the desalting process was removed by 50% ACN in 50mM ABC with the 
filter upside down. The protein mixture proceeded to further preparation procedures as following. 
Incubate Buffer (8.0 M urea and 10inmM DTT in 50mM ABC, pH 8.0) were added respectively 
to occur 50µL as the final volume L. The units were incubated at 37 °C for three hours. Additional 
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alkylating reagent (500 mM IAA in 50 mM ABC) was mixed finely with the samples with 50mM 
IAA as final concentration, which followed by 30-minute alkylation under darkness in room 
temperature. Then, each system was combined with 1.2 µl reducing reagent (1M DTT in DI water) 
to react with any leftover alkylating reagent. 450 µl of 50 mM ABC solution that contained Glu-
C under 1:100 enzyme- protein ratio inside was added to each sample so as to dilute high 
concentration of urea. After gently mixed on a vortex mixer, the sample systems were placed into 
37 °C incubator for Over-Night(O/N) digestion. Trypsin (under 1:25 ratio) was genteelly vortexed 
in the mixture following by the same time-length of incubator under identical condition. Further, 
the units were incubated for 5 minutes at 95°C to deactivate trypsin. Treated peptides were dried 
under Eppendorf Vacufuge Concentrator and stored in the -80°C refrigerator for further 
preparations. 
4.2.3 Results and Discussion 
4.2.3.1 The Comparison of Sequential Coverages between HA-1 and HA-2 under MED  
A schematic diagram of protein coverage determination for both proteins under multi-
enzyme digestion (MED) is shown in Figure 4.4.  
Two samples were performed under the workflow in Figure 4.4 in order to obtain the 
essential and reliable data respectively. Two purified HAs upon received were performed in-
solution or filter-aided sample preparation(FASP) digestion with certain concentration Glu-C and 
trypsin. Proteolytic peptides were further analyzed with a high-precision Orbitrap Elite under the 
same method in section 4.1. All the sequences were identified and mapped through pFind software. 
Obtained peptide mass fingerprinting mapping (PMFP) information was generated with peptides’ 
molecular weight and coverages. The coverage results under FASP technique are attached in 
Figure 4.5.   
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Figure 4.4 The Workflow Adopted for Multi-Enzyme Digestion 
The flowchart of multi-enzyme digestion is adopted in this study concerning improving protein 
sequence coverage to an acceptable range. 
 
Figure 4.5 Improved Coverage Results for HA-1 and HA-2 After MED Technique 
HA-1 and -2 were both treated with both MED and FASP techniques and achieved over 88% 
coverage respectively. Meanwhile, the results identified 5 out of 5 n-glycosylation sites which are 
discussed in chapter 4.3. 
4.2.3.2 MED Technique is Superior to Single-Enzyme Digestion Sample Treatment Based on 
Proteinaceous Coverage 
An available and comprehensive strategy, multi-enzyme digestion (MED), was designed 
in this section of the study. We did a further in-depth analysis with different factors that contain 
two digestion methods, single-enzyme digestion (SED) and MED, and two sample preparation 
techniques, FASP and IS. On the basis of our results, FASP is superior to IS in sample preparation 
technique level; MED gives better sequence coverage in the single tandem mass spectrometry 
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experiment. By adding one more enzyme, proteolytic peptide sizes dropped from 44 amino acids 
to 29 amino acids, which were included in the detection range of electron spray ionization (ESI) 
mass spectrometer, especially peptide fragment are more likely to be double charged by losing two 
electrons. Furthermore, FASP technique offers 50% more coverage than IS sample treatments. 
However, MED in FASP and IS methods didn’t show a recognizable significance within 20% 
peptide coverage of 100 amino acids, and the results from MED in each sample preparation 
procedures has distinct peptides identified from HA-1 and HA-2 respectively. Therefore, we 
performed both sample preparation processes in section 4.3 to further confirm our assumption of 
FASP’s advantage. 
There are several studies published to perform multi-step enzyme digestion (same enzyme) 
or multi-enzyme digestion (different enzymes) to increase protein sequence coverage and 
overcome sample complexity. In our study, we confirmed protein sequence coverage over 88% 
(Table 4.1) by applying MED and FASP techniques. Achieving consistent over 88% coverage 
offers a reliable and comprehensive identification for peptidemass fingerprinting technology. 
Furthermore, MED technique is usually flexible with enzyme selections as long as deactivation is 
included between each enzyme digestion. 
 
Table 4.1 HA-1 and HA-2 Digestion Methodology Comprehensive Comparison 
HA-1 SED MED HA-2 SED MED 
FASP 90.94% 88.87% FASP 69.18% 88.44% 
IS 73.40% 73.21% IS 40.38% 70.93% 
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4.3 The Verification of Theoretical Glycosylation Sites in HA and Determination of 
Glycosylation Occupancy for Each Specific Site 
4.3.1 Introduction 
For the past several decades, proteomics by mass spectrometry, especially quantitative 
proteomics has been an important technique for unrevealing and understanding the biological 
interaction in all organisms. Quantitative proteomics, to be more accurate, includes two major 
approaches – label-free quantification method and stable isotope labeling quantification technique 
[24]. Label-free quantification method has been mentioned in Chapter 3, whereas isotope labeling 
quantification will be well-explained in this chapter. 
Isotope-code labeling introduces mass shift to be compared to target proteins in biological 
samples, such as body fluids[105, 106], cancer tissues [107], and cells [108]. Up until now, an 
increasing number of approaches have been developed based on the selected pathway of isotopic 
label introductions. The ICAT (isotope-coded affinity tag) [109] is the first and well-developed 
chemical-isotopic labeling technique, frequently using deuterium or 13C. Besides many methods 
designed on the basis of ICAT principle, for example, ICPL (isotope-code protein labeling) [110] 
and SILAC (stable isotope labeling with amino acids in cell culture) [111], offering 15N-labeled 
amino acids like lysine and arginine through metabolic incorporation, are more frequently applied 
to cell cultures for a better functional understanding of target protein under in vivo condition. The 
technique we utilized in this chapter is enzymatic isotopic labeling strategy to provide a mass 
difference through the hydrolysis of peptide bonds in 18O-coded water [112]. Currently, 
glycoproteomics techniques are frequently the reapplications of proteomics methods previously 
mentioned, including ICAT, SILAC, etc.  
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In our study, we modified enzymatic isotope-code labeling pathway to introduce mass 
difference to asparagine in N-glycosylated peptides. In theory, PNGase F hydrolyses the covalent 
bond formed between glycan and asparagine – glycosylation site – in 18O water and introduces a 
molecular weight shift of 2.988. The isotopic difference on glycosylated asparagine is utilized as 
a variable modification to mark any glycosylation site. Furthermore, the routine enzymatic 
treatment offers a mass difference, 0.984, by changing asparagine to aspartic acid during 
hydrolysis. Meanwhile, the deamidation in protein occurs unavoidable and brings an identical 
mass change. Among these asparagines with mass shift, only the asparagines that follow a 
consensus pattern [N-X (X can’t be proline)-S/T] are generally considered as N-linked 
glycosylation sites. Thus, the advantage of our method is to prevent false positive identifications 
from occurring by introducing 18O.  
Hydrophilic interaction liquid chromatography (HILIC) is one of various 
glycopeptide/glycan enrichment techniques besides lectin affinity chromatography [113] or 
immobilized boronic acid application [114]. Commonly, silicon-based HILIC media is utilized as 
a hydrophilic stationary phase to interact selectively with a hydroxyl group in sugar residues under 
the existence of relatively hydrophobic mobile phase. According to the mechanisms of functional 
groups, HILIC is classified into following categories based on their functions: cationic exchange, 
anionic exchange, zwitterionic (ZIC) interaction, and sepharose. HILIC is capable of separating 
glycosylated peptides from digested unglycosylated fragments through interaction with 
hydrophilic sugar moiety. 
In this part, we combined multi-enzyme digestion with 18O isotope-code labeling and 
HILIC enrichment procedure consecutively for better identifications of N-glycosylation sites. The 
result shows that 18O isotopic labeling method offers more comprehensive coverages of all five 
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glycosylation sites in HA-1 and -2 and provides glycosylation occupancy information of each 
position within one run. 
4.3.2 Materials and Experiments 
4.3.2.1 Materials and Chemicals 
18O labeled water was purchased from Sigma, and ZIC-HILIC resin was obtained from 
Merck. The entire procedures are identical with two-enzyme digestion procedures in section 4.2. 
4.3.2.2 Enzymatic Deglycosylation in Isotope-Labeled Peptide Preparation 
The pallets after two enzyme digestion were resuspended in 50 µL G7 buffer in H218O (50 
mM Sodium Phosphate, pH 7.5) and incubated with peptide-N-glycosidase F (N-glycanase F, 
PNGase F) for 12 hours under 37 °C for deeper digestion following the published procedure 
previously [98]. The samples were dried in a vacuum concentrator and stored in a refrigerator at -
80 °C for LC-MS/MS analysis. 
4.3.2.3 N-Glycopeptides Enrichment and Enzymatic Deglycosylation in Peptide Preparation 
Approximately 100 µg of digested peptides were added into 25 mg ZIC-HILIC media and 
enriched by following the previously published procedures by Ma et.al. [31]. The entire 
enrichment procedures were performed using a self-packed tip-size column. The detailed strategy 
is as follows: C8 extraction disk was tightly stuffed into a 200 µl pipet tip; afterward, ZIC-HILIC 
media was suspended in 100 µl binding buffer (80% ACN, 5% FA) and injected into tips, the 
systems were equilibrated with the same buffer twice. Digested peptides gently thawed were re-
dissolved in binding buffer and loaded into 200 µl prepacked tip with six times desalting and 
washing procedure with 100 µl binding buffer per round. Bounded glycopeptides were eluted twice 
with 100 µl elution buffer (99% H2O, 1% FA). A vacufuge vacuum concentrator dried the well-
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prepared samples. Furthermore, enriched glycopeptides have followed the procedure described in 
section 4.1.2.5 to remove the sugars and introduce a 0.9840 Dalton mass difference. Additionally, 
the reaction solution can be stored in a refrigerator at -80 °C for further LC-MS/MS analysis. 
4.3.2.4 Data Processing and Determinations of Glycosylation Occupancy for Each Sites 
The sample acquired from 3.3.2.1 is following the procedures as below: 
This process has followed a publication from Dr. Ma [31] with some minor modification 
to reach the high results. The raw data were searched though the pFind 2.1 in HA-1 and HA-2 
protein database and its reverse sequences. The modifications were optimized: the static 
modification is Carbamidomethyl (Cys), and the dynamic modifications were generic: 
Deamination (Asn), Oxidation (Met) and Gln to pyro-Glu (Any N- terminal started with Q). The 
most significant modification is a 2.9883 Da mass difference, which was introduced when sugar 
cleaving process occurred in H218O. Trypsin and Glu-C were selected as the enzyme, and two 
missed cleavages were allowed. The mass tolerance of the precursor ion and the fragment ions 
mass tolerance were identical with the other procedures under the same FDR (false discovery rate). 
The peptides pallets from 4.3.2.2 were performed the same procedure as described in 
section 4.1.2.7. The database searching result was obtained from pBuild application with peptides 
mapping information. On basis of statistical accuracy, the peptides with score lower 1E-7 were 
chosen for the data pool. Spectrum number counting was selective for glycosylation occupancy 
quantitation. A list of potential peptide sequences covered glycosylation sites were generated with 
spectra number for isotope label and native Asp respectively. Further calculations were utilizing 
Microsoft Excel software.  
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4.3.3 Results and Discussion 
4.3.3.1 The Verification of Glycosylation Sites and Calculation for Each Glycan Occupancy 
Proteolytic peptides, including glycopeptides, were equally treated under two parallel 
strategies to ensure a full coverage of all five glycosylation sites. One approach is based on the 
idea of isotope-code labeling quantification by incubation within the 18O-labeled water. 
Meanwhile, glycopeptides were enriched through hydrophilic interaction with ZIC-HILIC media 
and further hydrolyzed with PNGase F. Sample slurries were ionized, detected, and then analyzed 
by reverse phase LC-ESI-MS/MS as shown in Figure 4.6. Raw data was analyzed with pFind to 
confirm both various and fixed modifications in target proteins, and initial PMFP result was 
collected with pBuild, including protein coverage information. Finalized results were screened in 
Excel sheet with selected peptides for further PMF analysis (Figure 4.8).  
 
Figure 4.6 The Workflow of Enzymatic Digestion in Isotopic Labeled Water 
The flowchart of PNGase F digestion in isotope label water combined with multi-enzyme digestion 
is adopted in this study. 5 out 5 glycosylation sites were mapped in these methods; that declared a 
higher sensitivity. 
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HA-1 and -2 both have five identical glycosylation sites in following positions: Asn32, 
Asn48, Asn251, Asn423, and Asn495. The glycopeptides with Asn495 were more challenging to 
identify during our study, which was caused by the undetectable size of proteomic fragments 
and/or low intensity for these glycopeptides. Nevertheless, five potential glycosylation sites were 
confirmed via our protocol and detailed peptide mass fingerprinting data was attached in Figure 
4.7. 
 
Figure 4.7 The Workflow of HILIC Enrichment Coupled Enzymatic Deglycosylation 
The flowchart of HILIC enrichment combined with PNGase F digestion is adopted in this 
experiment. 4 out 5 glycosylation sites were identified in this method. 
4.3.3.2 Comparisons between 18O and HILIC Approaches Relying on the Results from the 
Identifications of Glycosylation Sites 
According to previous studies, HILIC method is widely applied into polar or hydrophilic 
analyte purifications in biopharmaceutical applications, for example, saccharides [115], 
glycopeptides/glycoproteins [31], amino acids [116], polar basic compounds [117], metabolites 
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[118] and related polar molecules. Additionally, HILIC is more suitable for complex samples with 
various proteins, like body fluids. Our HILIC self-pack tip is easy to operate and with higher 
flexibility according to sample complexity. Enzymatic isotopic labeling, in comparison, is a 
conventional technology applicable for purified homogeneous sample system.  
In our study, two experiments were conducted with the two approaches under same 
conditions, such as sample amount, temperature, enzyme quantity, and incubation time. HA-1 and 
-2 were simultaneously treated with both approaches. Meanwhile, HA-1 and -2 showed similar 
results between two approaches: isotope-code labeling method is more appropriate and providing 
superior coverage of all five glycosylation sites than HILIC method. From Table 4.2, isotopically 
labeled quantitation has shown superior advantages in studying homogeneous protein system: 
Isotopic labeled quantitation required shorter sample preparation time relatively in comparison 
because HILIC demands one extra purified steps. The introduction of 18O improves the detection 
signal intensity of glycopeptides and offers better spectra to interpret each glycosylation sites. 
Detailed glycopeptides tandem mass matching graphs for N32 is attached in Figure 4.8 the rest 
of the graphs are enclosed in Appendix C.  
The calculation of glycosylation occupancy is based on the spectrum number counting. An 
alternative technique, peak area, was conducted as well. However, the efficiency of separation in 
the column is not optimal, the results from peak area calculation is not consistent with our initial 
result from spectra number counting. However, the peak area spectra from HA-1 is attached in 
Appendix D as a reference. Enlarged and unique mass shift cannot only distinguish these 
glycosylated asparagines from the ones under some unavoidable modifications – deamination, but 
also trace the ratios alternation of glycosylation occupancy on each glycosylation sites. The 
occupancy of each glycosylation site will be discussed in next section. Furthermore, isotopic 
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labeling approaches offer more detailed sample information in single mass spec data collection to 
verify protein sequence.   
 
Figure 4.8 Examples of Tandem Mass Spectra with Peptides included Glycosylation Site N32 
for HA-1 (Top) and -2 (Bottom) 
In contrast, HILIC method surpasses in contamination tolerance because of the designated 
wash process in the protocol. Considering the rigid limitation of salt existence in ESI mass 
spectrometer, isotopic labeling quantitation approach desires higher purity of samples in low-salt 
buffers. Thus, proper sample desalting and repurifying procedures may be considered before 
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PNGase F digestion. There is more to say that no water contamination is permissive during 
deglycosylation treatment to ensure properly labeling of 18O. 
Table 4.2 Compare HILIC and 18O Isotope Labeled Approaches 
 HILIC 18O 
Time Required for Sample Preparation 3-4 Days 2-3 Days 
Hardness of Sample Preparation Medium Easy 
Information Acquired from Single MS Run Limited Triple 
Cost < $100 per sample <$100 per sample 
Contamination Tolerance High 
Low (especially for 
water) 
Benefits to Data According and Processing 
Increase target 
peptide intensity 
Larger and unique 
mass shift, easy to 
detect modification + 
HILIC advantages 
Application 
Complicated sample 
type, such as body 
fluid 
Purified single 
protein (better) and 
complicated sample 
 
Table 4.3 Average Occupancy Ratio Results for Five Potential Glycosylation Sites in HA-1 
and HA-2 
Glycosylation Site Occupancy Ratio HA-1 HA-2 
N32GT 22.2% 20.0% 
N48AT 63.6% 64.7% 
N251DT 25.0% 14.3% 
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N422WT 67.6% 63.0% 
N459NT 50.0% 87.5% 
4.3.3.3 The Determination of Occupancy Ratio for Glycosylation Sites in HA-1 and HA-2 
The entire design of this section was due to the initial unsuccessful a-gal study in chapter 
4.4. We assumed that the incapability to quantitate a -gal is the reason of incomplete interaction 
between oligosaccharides and peptides. In consequence, 18O-isotope code labeling approach offers 
the information of peptide fragments with/without glycan attached. The raw data files obtained 
from experiments in section 4.3.2 were reevaluated for glycosylation occupancies. The ratio of the 
formerly glycosylated asparagine over the non-glycosylated asparagine (and thus the site 
occupancy) is calculated by comparing the spectra number of the deglycosylated peptide against 
the non-glycosylated peptide. The glycosylation site occupancy result was included in Table 4.3. 
HA-1 and -2 have enormous significant differences of glycosylation site occupancy in N251 and 
N459 positons. In HA-1, none of the sites has occupancy higher than 70% that may cause the 
unsuccessful detection of terminal glycans. As mentioned in Chapter 1, disease-related aberrant 
glycosylation may be associated with protein expression or glycosylation changes. Therefore, 
quantitative evaluation of glycosylation change in site-specific level can provide better 
understanding abnormal diseased-associate changes in protein level or in complicated specimens 
[119]. However, we didn’t receive enough background for us to make any hypothesis of HA-1 and 
HA-2. Furthermore, this method to determine glycosylation occupancy is appropriate to other 
glycoproteins. 
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4.4 Quantitative Determination of Terminal a-Galactose and Structural Analysis of 
Attached Sugar Moieties 
4.4.1 Introduction 
Alpha-1,3- galactose, typically called alpha-gal, is a terminal glycan structure in a definite 
consensus pattern of galactose-alpha-1,3- galactose-R [120]. Alpha-Gal is a basic sugar moiety 
that expressed in mammalian cells excluding human and higher evolved primates [121]. As a result 
of the non-existence in human, hyperacute allergy reaction, such as anaphylaxis [122], can be 
activated rapidly and lethal. On basis of the pieces of literature reported [122-124], tick bites are 
one of the causes of generating IgE antibody against alpha-Gal around the world. In the meantime, 
introducing alpha-gal into a human through xenotransplantation of organs, xenogenetic heart 
valves for example, from pigs can trigger similar severer reactions and consequently a rejection of 
transplantation, and a low percentage of IgG and IgM are commonly responsible for the 
complement cascade [125]. Alpha-Galactose allergy, or red meat allergy, is manageable by 
avoiding consuming any red meat. However, there is no absolute cure for alpha galactose allergy 
like any other autoimmune deficiencies.  
In order to understand the functional connection between glycan moieties and 
glycoproteins, increasing attentions have been drawn into the field of glycomics and 
glycoproteomics, especially under the rapid development of mass spectrometer associated 
technologies. The configuration and structures of glycan moiety actively regulates the function 
and pharmacokinetics of glycoproteins. The terminal sugars on immunoglobulins are various in 
their natural forms or human modified monoclonal antibodies. When terminal sugar is GlcNAc, 
IgG has a short half-life in serum [126]; Sialic acid is a type of common terminal sugars that exists 
  78 
in N-glycans from various serum glycoproteins, the appearance of terminal sialylation extends the 
half-life of these glycoproteins in serum [127].  
Several glycan sequencing approaches were developed to sequence properly released 
glycans from glycoproteins. For example, permethylated oligosaccharides analyzed by mass 
spectrometer [1, 128], fluorescent tags labeled glycans combined with exoglycosidase treatment 
[129], or tandem mass spectrometry using LC-ESI-MS/MS or MALDI (matrix-assisted laser 
desorption ionization) [1]. In spite of any techniques, the beginning of sequencing carbohydrates 
starts from releasing the carbohydrate moieties from peptide backbone using appropriate 
endoglycosidases, especially N-glycans can be efficiently released by PNGase F. Among these 
glycan sequencing strategies, reductive amination is the most common reaction applied in the field. 
Most often, released oligosaccharides can be labeled at their reducing end using the labels with 
either fluorescent or UV-absorbance. 2-aminobenamide (2-AB) is the most widely employed 
labels in chromatography [130]: the strategy of 2-AB- labeled glycans in HILIC with fluorescence 
detection has been standardized for glycan structural study, extensive detailed knowledge – LC 
gradient, oven temperature, or elution time for each sugar – are accepted in these protocols [131]. 
This derivatization approach has a superior capability to tag and truly quantify each glycan on the 
basis of the fluorescence intensity. 
High-performance anion exchange chromatography with pulsed amperometric detection 
(HPAEC-PAD) has been developed as a technique offering a sensitive detection and efficient 
separation for carbohydrate analysis for the past 30 years [132]. Because sugar molecules show 
the property as weakly acidic anions in basic solution [133], the combination of pulsed 
amperometric detection with a gold working electrode serves as an outstanding technology with 
highly sensitivity and selectivity for the determination of monosaccharides, oligosaccharides, and 
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glycolipids or so. Meanwhile, the excellent reliability of analysis from HAPEC-PAD makes it a 
usual tool for many fields, such as food, agriculture, medicine, and biotechnology. In comparison 
with HPLC, HPAEC-PAD provides remarkable separation of underived sugars in lower 
concentrations with significant shorter columns. Additionally, monosaccharides elute immediately 
without binding with a column in HPLC. However, HAPEC-PAD is not capable of being on-line 
with ESI-MS because of the high salt concentration in fractions. It is more common to analyze 
fractions in MALDI mass spectrometer after a brief desalting procedure. Meantime, HPAEC-PAD 
lacks commercial standards for oligosaccharides [134]. Furthermore, HPLC overcomes the low 
sensitivity and selectivity of oligosaccharides by deriving carbohydrates with labels that have 
fluorescent absorbance.  
In this study, we examined multiple approaches to quantify the percentage of alpha- 
galactose in HA-1. The combination of 2-AB labeling and exoglycosidase hydrolysis was the final 
approach applied to our study. We experimentally developed a combined application of glycan 
acid hydrolysis and HPAEC-PAD. However, the uncomprehensive glycoconjugate in HA cannot 
offer sufficient amount of oligosaccharide to exceed the instrumental limit of detection (LOD). 
Therefore, our novel developed methods mentioned here are more applicable to the understanding 
of high-glycosylated proteins. The second we developed here can successfully identify terminal α-
galactose and quantitate the percentage of galactose utilizing HPLC with fluorescence detector to 
determine by the fluorescent absorbance of 2-AB labeled sugars. After MALDI-MS/MS analysis, 
the results were shown that only 0.02% of target galactose among total oligosaccharides released 
from the HA-1 backbone. This technique is appropriate to quantitate and determine proteinaceous 
glycan structures quantitatively and qualitatively.  
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4.4.2 Materials and Experiments 
4.4.2.1 Materials and Chemicals 
The following chemicals were obtained the highest grade available from Sigma-Aldrich 
Co (St. Louis, MO, USA): 2-amino benzamide (2-AB), dimethyl sulfoxide(DMSO), acetic acid, 
trifluoroacetic acid(TFA) and sodium cyanoborohydride. HPLC-grade acetonitrile, methanol, and 
water were from Fisher Scientific (Fairlawn, NJ, USA). Nonporous graphitized carbon 
(Carbograph) solid-phase extraction (SPE) columns (150 mg/ 4mL) were obtained from Alltech 
Associates (Deerfield, IL, USA). PNGase F, trypsin, and Glu-C were purchased from New 
England Biolabs (Ipswich, MA, USA). 
4.4.2.2 Enzymatic Releasing of Glycans 
N-glycans were released from 600 µg of HA-1 with Peptide-N-glycosidase F (PNGase F) 
(200 units) in 50 µL of 50mM ammonia bicarbonate; the unit was incubated for 12 hours under 37 
°C water bath. The mixture was treated with ice-cold methanol to deactivate and precipitate 
protein, and the supernatant was aliquoted into two portions and dried in a speed-vac concentrator 
afterward.  
4.4.2.3 Hydrolysis of Oligosaccharides into Monosaccharides 
Two parts of N-glycans (equivalent to the amount of sugar from 1mg HA-1 and HA-3) 
were respectively treated with neutral and amino sugars or sialic acid. Two approaches are using 
similar procedures: 2M TFA was added into neutral and amino sugars samples and incubated under 
100oC for 4 hours; similar to this, one sialic acid solution was combined with 2M acetic acid and 
incubate under 80oC for 3 hours. To offer an accurate and consistent temperature, dry metal block 
bath is more preferred than a water bath. N2 dried samples were reconstituted with 200 µL water 
for HPAEC-PAD analysis. 7 sugars standards (fucose, glucose, galactose, n-acetylgalactosamine, 
  81 
n-acetylglucosamine, mannose, sialic aid) divided by their prosperities into two parts: neutral and 
amino sugars (fucose, glucose, galactose, n-acetylglucosamine, mannose), and sialic acid. The SA 
is under different concentrations (0.02 µM, 0.04 µM, 0.06 µM, 0.08 µM) for a calibration curve. 
The concentrations of neutral and amino sugars were (5 nM, 10 nM, 15 nM, 60nM). 20 nM of 
glucose, internal standard, was spiked into HA-1 and -3 samples. Sugar standard calibrators were 
hydrolyzed under the same procedures as described above. 10 µg of each monosaccharide and 7 
sugars mixture detected without hydrolysis.   
4.4.2.4 Monosaccharide Quantitation with HPAEC-PAD 
Monosaccharides were separated at 0.4 mL/min flow rate on a Dinox CarboPac PA-100 
column (4 x 250mm) with compatible guard column under following multi-step gradients (Table 
4.4). The mobile phase is 200mM NaOH, mobile phase B is 500mM NaAc, and C is HPLC-grade 
water. Each mobile phase is degassed and filtered before using. The temperature for the column 
oven is set to 30 oC. Back pressure of the column is usually around 900-1500 psi. 
Table 4.4 Gradient Chart for Monosaccharide Separation on HPAEC-PAC 
Minutes A% B% C% 
0.0 2.5 0 97.5 
20.0 2.5 0 97.5 
45.0 50 30 20 
45.1 2.5 0 97.5 
60.0 2.5 0 97.5 
60.0 Stop Run 
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4.4.2.5 Conjugation of Glycan to 2-Aminobenzamide (2-AB) 
One portion of dehydrated glycans was dissolved in 50 µL labeling agent (50 mg/mL 2-
AB and 1 M NaBH3CN in DMSO/acetic acid (7:3, v/v)) before incubation at 65 °C up to 2 hours. 
The labeled glycan mixture was loaded onto an SPE column that prewashed with 5 mL of ACN 
and 5 mL of water. Theoretically, the salts and other impurities were removed by 15 mL of water, 
and the target derivatives were eluted with 4 mL of 25% acetonitrile containing 0.1% TFA. The 
elutes dried for the following enzymatic reactions. 
4.4.2.6 Exoglycosidase Digestion on 2-AB Derived Glycans 
The entire procedure was carried out in a 37oC water bath. The dried glycans were 
resuspended in 30 µL volume of 1X glyco-buffer 1(G6 reaction buffer: 50mM CaCl2 and 50mM 
Sodium acetate, pH5.5 @25 oC). Each enzyme was thoroughly added and mixed after 10-minute 
boiling denature process and was incubated for 24 hours at 37 oC by following the order: α2-3,6,8 
neurominidase, b1-4 Galactosidase, a1-2,4,6 fucosidase. The mixture after digestion without 
purification was injected into HPLC.  
4.4.2.7 Chromatographic Separation and MALDI Analysis of Glycan Derivatives with 2-AB 
Labels 
Around 10 µL oligosaccharides were injected into Shimazu Nexera x2 ultra High 
Performance Liquid chromatography system with a fluorescence detector. The XBridge amide 
HILIC column with following configurations was applied: 3.5 um, 4.6 x 150 mm. Oven 
temperature was 40 oC. Fluorescence detector were set as l excitation=320 nm, l emission =420 
nm. Phase A is 50mM ammonium formate solution with pH 4.5; phase B is HPLC-grade 
acetonitrile based on Tayi’s protocol [135]. Glycan fractions were separated as following gradients 
(Table 4.5) and collected for further analysis. 
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The sample fractions were dried in a speedvac vacuum concentrator and stored in -80°C 
refrigerator for further preparations. This procedure was performed on ultrafleXtreme MALDI-
TOF-TOF mass spectrometer with flex method by using 2.4-dihydroxybenzoid acid (DHB) as the 
matrix. All 23 fractions were spotted on an MTP 384 target plate (ground steel) The tandem mass 
results acquired were analyzed using GlycoWorkBench software, glycan spectrum-structure 
mapping results were identified by matching MS2 ion peaks against CFG glycan databases. 
Further mapping information is discussed in result section 4.4.3. 
4.4.2.8 Enzymatic Activity Confirmation of Alpha 1-3,6 Galactosidase by Dot Blot 
Deactivated HA-1 was treated with different ratios of α1-3,6 galactosidase for 24 hours. 
The enzyme to protein ratios were 100: 32, 100: 16, 100: 8, 100:2, positive and negative control. 
Proper nitrocellulose membrane was marked with pencil and spotted 2 µl of samples in each spot. 
Dried membrane was blocked following the same procedures as Western Blot. The primary 
antibody (1:1000 for HA-1) and the secondary antibody conjugated with HRP (1:1500) were 
particularly applied to HA-1. The concentration was confirmed between samples. 
4.4.2.9  Removal of Terminal a-Galactose with a1-3,6 Galactosidase 
All the conditions and procedures are following section 4.4.2.6 with a1-3,6 galactosidase. 
Table 4.5 Gradient Chart for Derived Sugars’ Separation on HPLC-FL 
Minutes %A %B 
0 10 90 
60 50 50 
70 90 10 
71 10 90 
80 Stop Run 
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4.4.3 Results and Discussion 
4.4.3.1 Experimental Design Scheme for Hydrolyzed Monosaccharides Quantitation and 2-
AB Labeled Sugar Quantitation 
Sequencing of complex glycan mixtures is usually handled from either monosaccharide 
perspective or sugar moieties level. Oligosaccharide derived from HA-1 were digested with alpha-
1-3,6-galactosidase and checking reaction progression simultaneously by Dot-blot. Further, 
samples are hydrolyzed under the acid condition to monosaccharides. Monosaccharides were 
quantified with HPAEC-PAD (Figure 4.9). 2-AB labeled glycans were assigned as the second 
approach: released glycans were tagged with reductive labels initially, the slurry was incubated 
with a series of continuous exoglycosidases to remove terminal sugars. These fragments were 
separated utilizing HPLC with fraction collector in HILIC column. Dried fractions were detected 
with MALDI (Figure 4.10). 
 
Figure 4.9 A Scheme of Sugar Hydrolysis Coupled HAPEC-PAD Method 
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Different units of a1-3,6 Galactosidase were incubated with 100 µg of HA-1 for 12 hours. The 
average concentration of 2U and the positive control was taken to as the number of positive 
control. 
 
Figure 4.10 A Diagram of 2-AB Derived Glycans Analysis with HPLC and MALDI-MS/MS  
Derived carbohydrates with 2-AB labels were hydrolyzed with exoglycosidases and separated by 
an HILIC column in a gradient method of HPLC with a fluorescence detector. The collected 
fractions were dried and reconstitute with DHB in 50% ACN. 23 fractions were spotted on a 384 
polished MALDI plate. Results were interoperated manually and confirmed with CFG database. 
4.4.3.2 a1-3,6 Galactosidase Activity Verification Using Dot Blot 
Various unites of α1-3,6-galactosidase were incubated with 100 µg of HA-1 as shown in Figure 
4.11. The positive control was HA-1 with no enzyme, while negative control, HA-3, was provided 
by the collaborator. It was an analog of HA-1 without terminal galactose attached in alpha 1-3 
configuration. From analyzing our result, the perfect reacting ratio is around 100: 4 (enzyme to 
protein) in 12-hour incubation. Extended incubation time can proceed to completion with fewer 
units of the enzyme [136, 137]; thus we extended our incubation time to 24-hour in 37 oC water 
bath, which offers more steady temperature and humidity than incubation chamber. However, the 
reaction unit with the highest concentration of galactosidase was showing false positive results. 
Many reasons can trigger false positive results: poor blocking effect, strong binding between 
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galactosidase and substrate, or competitive inhibition between existing antigens in samples [138]. 
With comprehensive blocking procedure, the applicable possibility is that denatured galactosidase 
competitively binds with the primary antibody. Galactosidase removes the terminal galactose in 
α1-3 configuration, and may keep that monosaccharide in the active site and prevent completing 
the reaction. When primary antibody added in, it targets those alpha galactoses on both the subtract, 
HA-1, and inside catalytic pockets. The level of reactions was determined based on the darkness 
of spots (Table 4.6).  
 
Figure 4.11 The Dot Plot Results of a1-3,6 Galactosidase Activity Determination 
The same quantity of HA-1 protein was combined with various concentrations of a1-3,6 
galactosidase. The optimal ratio between protein and enzyme (100µg to multiple units) is from 
100: 4 - 100:8 with prolonged incubation time. 
4.4.3.3 Quantitation of Monosaccharides from Released Glycans with HPACE-PAD 
The intention of this experiment is to quantitate a-Gal in either percentage level or weight 
level. We artificially removed terminal galactose at α-position in HA-1 and confirmed reaction 
completion in Dot-blot. Then, derived oligosaccharides from intact HA-1(with α-gal) and treated 
HA-1 (without α-gal) were hydrolyzed into monosaccharides simultaneously as long as 
monosaccharides standards. The quantity of α-gal, hypothetically, is capable of being calculated 
by subtracting galactose concentration in treated HA-1 from the concentration from intact HA-1. 
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However, our data has not shown any traces of monosaccharides above the limit of detection 
(S/N=3) and/or limit of quantitation (S/N=5).  
Released carbohydrates from intact and treated HA-1 protein were hydrolyzed into 
monosaccharides for quantification in HPAEC-PAD. Calibrators were treated under the same 
protocol before HPAEC-PAD quantitation.  
As following, elution times for monosaccharide and the 7-sugar standard are shown in 
Figure 4.12. After hydrolysis treatment, the retention time for each sugar is shortened as shown in 
Figure 4.15. Galactose has shown a lower affinity and sensitivity compared to other 
monosaccharides in the picture. The linearity of each standard curve, neutral and amino sugars and 
SA that determined with their peak areas, is acceptable as larger than 0.9850 (Figure 4.13 and 
4.14). A table is attached in Appendix B including the peak area and retention time for 
monosaccharides.  
In each run of HA-1 hydrolysate, no monosaccharide was identified in the limit of detection 
besides the internal standard, glucose. In Figure 3.15, Peak 2 and Peak 3 respectively are from 
internal standard, glucose, in HA-1 and HA-3 samples. According to our collaborator’s description 
(Figure 4.16), detection of glucose from HA-1 and HA-3 is impossible because of the glucose 
Table 4.6 The Chart of a1-3,6 Galactosidase Activity  
QEnzyme 32U 16U 8U 
Trial # 1 2 3 1 2 3 1 2 3 
Darkness 7.7 6.6 7.9 2.3 2.4 1.4 3.0 2.9 3.4 
Mean 7.4 2.0 3.1 
% 80 100 95 
QEnzyme 2U Positive Control Negative Control 
Trial # 1 2 3 1 2 3 1 2 3 
Darkness 39.7 37.1 36.1 18.0 19.2 18.9 2.2 2.5 1.0 
Mean 37.6 18.7 1.9 
% - - 100 
  88 
abundance in mentioned carbohydrates. 25.7nM and 18.1 nM of Glu were quantitated from HA-1 
and -3 respectively. Fucose was determined from both samples with 16.9 nM and 10.9 nM in 
concentration. GlcNAc has detected from both proteins also relaying on the retention time, 21.9 
nM and 16.3 nM. After triplet injections of each sample, we concluded that HA-1 is more core-
fucosylated than HA-3; meantime, 4.78 nM of glycan, the most dominate biantennary structure in 
Figure 3.16, were quantitated from 15.0 nM of the intact protein, which means only 30% of HA-
1, in average, were glycosylated; among these, 0.067% is galactose with α1-4 configuration 
regarding the results from 2-AB labeled quantitation method.  
 
Figure 4.12 Elution Times for 7-Sugar Standard and Monosaccharides 
Based on the bottom figure, the retention time of each monosaccharide can be confirmed and 
identified from the 7-sugar standard graph. In PA-100 column, the quality of buffer affects the 
retention time. However, the elution order of monosaccharides is consistent. 
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Figure 4.13 Standard Curve of Sialic Acid 
 
Figure 4.14 Calibration Curve for Neutral and Amino Monosaccharide 
However, the determination of galactose is unapproachable with this technology. In order 
to obtain acceptable peak separation and resolution from HPAEC-PAD, the desirable concertation 
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of a monosaccharide, especially galactose, should exceed 10 nM, which equals to 600 µg of HA-
1 if we consider HA-1 as 100% fully glycosylated with 11 sugars in each glycosylation site. As 
mentioned in the previous chapter, we confirmed the glycosylation occupancies for HA-1 and HA-
2 respectively. For example, the average glycosylation site occupancy for HA-1 is lower than 50%, 
and each is lower than 70% respectively. Therefore, using HPAEC-PAD as a detection technique 
requires a numerous amount of target protein, over 1 mg. However, it is no doubt that HPAEC-
PAD offers a high sensitivity and selectivity with a proper column. Meanwhile, it serves as a 
sufficient tool to monitor glycosyltransferase reaction with an injection of a small quantity of 
supernatant. 
 
Figure 4.15 Spectra of HA-1 and HA-3 Obtained From HPAED-PAD 
No galactose was detected in the samples; glucose was spiked into the sample as internal standards. 
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4.4.3.4 Exoglycosidase Treatment of 2-AB Derived Glycan 
Exoglycosidase digestion combined with MALDI-TOF mass spectrometry has been an 
effective and efficient way to sequence the N-linked glycans from a glycoprotein [129]. The 
technique that couples exoglycosidase treatment with HPLC is more sensitive and reliable with 
derived glycans: HPLC offers excellent separation and collects the fraction for further enzyme 
digestion and structure confirmation [78]; the use of exoglycosidase enzyme is essential to acquire 
the information of linkage and sequence of glycans simultaneously. Because of the inefficiency of 
β1-2,4 GlcNAcase, only enzyme 1, 2, and 4 were tested in our experiments (Figure 3.16). 
Following incubation, one-step enzyme deactivation in between adding each enzyme, these 
exoglycosidases were separately mixed into the reaction for 24-hour. The list of exoglycosidase is 
attached in Figure 4.16.  
 
Figure 4.16 A Scheme that Shown Various Exoglycosidases’ Functions and Aim Sites 
5 major glycosidases were applied in this experiment, the two complex structure of glycans 
are the possible glycoforms provided by our collaborator.  
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In this study, our purpose is to confirm the quantity of terminal galactose, which is in alpha 
1-4 configuration with galactose. The glycans were derived with the 2-AB label (Figure 4.10) after 
released from peptide backbone with following retention times. The molecular weight of the sugar 
increased 120.0687 Da following the chemical reaction mentioned in Figure 4.17 underneath. On 
the basis of the description from our collaborator, the potential structures of carbohydrates are 
drawn in Figure 4.16 with/out core fucose – fucose alpha1-6 linked with the reducing GlcNAc. 
Therefore, one-pot enzyme reaction is more applicable for this experiment instead of monitoring 
the extent of each reactions using HPLC. However, we prolonged the incubation time as long as 
the existence of excessive enzyme in order to ensure the comprehensive activity of each 
glycosidase [84, 139]. However, we discovered 13 types of glycans that include only a small 
portion of our target from 24 fractions we collected by HPLC (Figure 4.18). Theses carbohydrates 
are identified with 4 man, 5 man, hybrid and a majority of complex structures. 5 out of 18 
glycoforms were not declared in the possibility list. Among these structures, the percentage of 
alpha-gal is 0.067% based on peak area obtained in a fluorescent detector (Table 4.7). In other 
words, only 0.067% is our target among released oligosaccharides from HA-1. This result is much 
lower than the assumption and expectation of our collaborator. The list of the glycan structure we 
identified was attached in Table 4.7, and MALDI spectra and related interpretation diagrams are 
attached in Appendix A.  
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Figure 4.17 The Scheme of 2-AB Labelling Reaction 
In theory, the activity of each enzyme is not certain 100 % even though we added excessive 
enzyme and prolonged the incubation time, especially β1-4 galactosidase, more efficient with 
simple sugar, like lactose. Hydrolysis is more likely to happen when a large excess of water exists 
in the environment. Several enzymes were showing low activity of removing the target glycans; 
the reasons were stated as following: 1. The entire enzymatic hydrolytic process was operated in 
the same buffer, glyco-buffer 1. Between steps, the denature procedure – hot water bath – would 
affect pH, salt concentration and the reaction volume of the reaction system. When enzyme 
precipitate, the subtract in the active sites may not be released, which in consequences lower 
subtract quantity; meanwhile, the protein can envelop salt or water in surrounding to influence the 
reaction environment. Since the hydrolytic approach is an equilibrium-controlled reaction, which 
means milder conditions [140], the minor alteration in the condition substantially differentiates the 
activity of each enzyme. α1-2,4,6 Fucosidase was the last exo-acting enzyme into the system, and 
the reason mentioned above may explain the lower clearance ratio of fucose on these glycosidic 
moieties. Furthermore, most of the exohydralases are double enzymes that control hydrolysis and 
reverse hydrolysis. The increasing amount of monosaccharides in the reacting solution could 
inhibit the activity of these enzymes and trigger the early coming of undesirable equilibrium point 
in hydrolytic reactions.  
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Table 4.7 The List of Sugar Structures Identified from Derived Labeling Technique 
Peak # Glycan Structure m/z in Dalton Peak Area 
Peak 
Percentage 
2  1255.8755 2795331 4.287 
6  1459.1709 418648 0.642 
7  1605.0888 3625416 5.56 
8-1  1377.2113 16155770 24.777 
8-2  1605.1021 - - 
9  1662.1943 1092057 1.675 
10-1  1362.2843 10540431 16.165 
10-2  1808.3703 - - 
10-3  1824.3480 - - 
11  1808.2474 1016339 1.559 
12  1565.2543 5970020 9.156 
14  1768.5025 5057791 7.757 
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15-1  1622.4119 56600 0.087 
15-2  1768.4876 - - 
17  1727.6112 30108 0.046 
19  1784.4987 13846 0.021 
23 
 
2092.7482 437724 0.671 
 
Two out of 18 structures were discovered with terminal α-galactose (Labeled in red) that comprises 
0.067% of the total identifications based on peak area. The MALDI results and Mass-Structure 
Mapping with CFG database are contained in the appendix.  
 
ESI offers better sensitivity and resolution in analyzing small molecules with clearer 
spectrum and lower noise; however, MALDI-MS/MS is the optimal choice for our study. Since 5 
identical injections were introduced to HPLC, each fraction is over 1mL. This large volume of the 
sample exceeds the carrying capacity of a C18 column on one hand; on the other hand, ammonia 
formate in the elution buffer increases noise signal. Meanwhile, it may contaminate the ion source 
and block the ion source needle. In contrast, a small quantity of salt facilitates the ionization 
efficiency and spikes the sample signals. The only drawback of MALDI-MS/MS is the off-line 
connection from HPLC because the removal of solvent in fractions is essential for MALDI analysis. 
Meantime, this off-line design may increase the possibility to introduce random error into the 
system. 
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Figure 4.18 The Spectra from HPLC with a Fluorescent Detector 
24 peaks were detected and collected through HPLC collector. A total number of 5 injections were 
made to assure reliable separation ability and determinate retention time in the HILIC column, 
each injection contains an identical amount of sample.  
4.5 Conclusions 
In this study, we initially mapped HA-1 and -2 proteinaceous sequences using PMF and 
achieved a nearly 90% coverage of peptide fragments. Further, a total of 5 potential glycosylation 
sites were completely confirmed with acceptable peptide-spectra mapping results. Additionally, 
glycosylation occupancy for each site was various that influenced the quantitation of alpha-
galactose experiments. Applying the technique that exoglycosidases coupling with HPLC, 0.067% 
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of terminal galactose in α1-4 position was quantitated from 100 µg HA-1. A total of 17 
carbohydrates were identified from the released sugar moieties. Among those, novel n-glycan 
structures, high mannose (two structures) and hybrid (three possible forms), were discovered in 
HA-1 besides the known complex structures in our assumption. The technologies developed in 
this chapter can offer a novel approach to understanding comprehensively and study the structural 
and functional properties of any glycoproteins. 
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CHAPTER 5.  Conclusions 
5.1 Project Conclusions 
The overall aim of this Ph.D. dissertation is to study thoroughly the structures of N-glycans, 
and the potential outcomes of N-glycosylation to proteins or molecules in biological specimens or 
biopharmaceuticals (monoclonal antibody and HA-1), and further to comprehend the connection 
between structure and function. Modifications in N-glycosylation sites are triggered by 
environmental changes in cells when diseases cause physical and pathological differences. 
Frequently, these alterations have robust impacts on the structure, function, and pharmakinetics of 
therapeutic proteins or these markers. Currently, many glycoproteins have been recognized as 
biomarkers for many cancers and autoimmune deficiencies. However, because of the non-pattern 
nature of protein N-glycosylation, it has been considered as one of the most complicated post-
translational modifications. Meanwhile, glycoprotein frequently has multiple glycosylation sites 
(HA-1), and various glycoforms in one particular site (mAb). Due to the correlation between N-
glycosylation and diseases, there have been a rousing number of studies published on developing 
novel methods and technologies of mass spectrometer to improve identification and quantification 
of N-glycoprotein. Comprehensive quantitative analysis of protein N-glycosylation in this 
dissertation includes the quantitation of glycosylation alteration site-specifically and global or 
sugar-specifical, determination of glycosylation occupancy at each site and identification of 
glycoforms in therapeutic proteins. 
To increase the sensitivity and identified information related to N-glycosylation, analytical 
techniques with high resolving power are demanded in quantification. Furthermore, an improved 
sample preparation approach had to be developed to enable analysis of clinical specimens. In 
Chapter 2, trypsin digestion coupled with HILIC tip-enrichment was applied to rheumatoid 
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arthritis biomarkers’ screening. N-glycosylation alteration is studied globally and site-specifically, 
which means the variation of the glycosylation site may associate with either protein expression 
or glycosylation sites specific changes. Thus, verification of global expression and site-specific 
alteration is conducted in Western-blot. The complement system plays an influential role in the 
human immune system against RA. Over 17% of the glycosylation sites identified are from or 
associated with the complement system. The change of glycosylation occupancy indicates a 
possible means for distinguishing RA from other immune system deficiencies, and many other 
applications are available with this method. 
The monoclonal antibody has one highly-identified glycosylation site, N274, with multiple 
glycoforms attached. In Chapter 3, we designed a fast and efficient method combined HILIC 
enrichment technique higher-energy dissociation- MS2, without 1/3 cutoff influence of CID. In 
other words, HCD receives more essential information on the fragments generated from sugar 
moieties; this information is very crucial for identifying core-fucose structure. Furthermore, based 
on our study, manual interpretation is shown to offer more accuracy and various structures in 
glycan structural analysis than some commercially available software. A total of 13, from 26 
overlapped glycoforms, were identified with significant alteration between standard and modified 
monoclonal antibody samples. Manual interpretation of glycan structure provides a reliable 
approach to research carbohydrate moiety fully and to establish a structure-function correlation 
between carbohydrate branches and glycoprotein. This technique can be further applied for site-
specific glycan structure analysis. However, MI strategy is time- and man power-consuming, 
additionally it required adequate knowledge in glycoscience to decipher the structures. For 
glycoprotein with multiple glycosylation sites, the workload is dramatically increased since the 
miscleavages from enzymatic digestion exponentially rise the mass set of potential peptide 
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backbones. Our desire is to optimize the fragmentation database for N-glycan so that software 
companies are driven to improve accuracy and affordability of their products.  
A comprehensive study of therapeutic protein offers better understanding and predicting 
the efficiency and safety of the product. In Chapter 4, we designed several approaches to verify 
the proteinaceous sequence of HA-1 and -2, to determine glycosylation sites and glycosylation 
occupancy for each site, and to quantitate the percentage of one sugar block, galactose. The entire 
procedure is described as Figure 3.6 in detail. Multi-enzyme digestion was the most comprehensive 
and highly reproducible technique to offer sufficient coverage, over 80%, in proteomic 
perspective. The nano-LC-MS/MS mass spectrometric method in combination with stable heavy 
isotopic labeling was advantageous compared to nano-LC-MS/MS combined with HILIC 
enrichment. In order to achieve α-galactose quantitation, 2-AB derived glycans associated with 
exoglycosidase digestion was optimized by sample preparation, HPLC separation, and MALDI 
detection. Furthermore, the method was qualified with respect to linearity, reproducibility, and 
robustness. 0.067% of target sugar building block were detected from HA-1.  
5.2 Suggested Future Applications 
Overall, this dissertation focuses on the development and application of mass spectrometric 
assays for characterization and quantitation protein N-glycosylation – globally and site-
specifically – and a specific monosaccharide, and the techniques of glycan structural 
determination. These results are envisioned as a potentially valuable approach for uncovering more 
perspectives of the structure-function relationship between glycan moiety and protein backbone. 
Many future works are demanded to improve or expand the application of these assays. Currently, 
there is a high demand for establishing databases of signature signals from specific N-glycans or 
distinctive therapeutic proteins, especially commercially available software is continually 
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improving and desperately waiting for that information. The other techniques are potentially 
omnipotent to quantitative and characterize N-glycosylation and the related area in glycomics and 
glycoproteomics.   
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 APPENDICES  
Appendix A  
24 fractions were collected and analyzed by MALDI-MS/MS, 19 sugar structures were detected 
from these. All the spectra and results from manual interpretation were attached underneath.  
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Appendix B  
Table 1 Retention Time and Peak Area of Hydrolyzed Monosaccharide Using HPAEC-PAD 
 Fucose Galactose Glucose Mannose GlcNAc  SA 
Con. 
(nM) 
RT Area RT Area RT Area RT Area RT Area 
Con. 
(nM) 
RT Area 
5 3.46 0.38 6.91 1.06 8.70 3.07 9.86 0.43 11.78 0.33 20 5.84 2.342 
10 3.45 0.800 6.88 1.894 8.68 5.378 9.85 0.859 11.77 0.748 40 5.84 4.384 
15 3.43 1.112 6.84 2.702 8.63 7.479 9.85 01.301 11.69 1.137 60 5.85 6.323 
60 3.40 7.393 6.78 12.118 8.55 34.707 9.75 8.982 11.60 6.935 80 5.86 8.714 
Appendix C  
 
Figure 1 Tandem Mass Spectra Taken from pLabel Showing Matches to Peptides Included 
Glycosylation Site N48 for HA-1 and -2 
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The glycosylation occupancies for N48 site is very similar between HA-1(Top) and HA-2 
(Bottom). However, the enzymatic-generate fragment in -1 is bigger than -2. 
 
Figure 2 Tandem Mass Spectra Taken from pLabel Showing Matches to Peptides Included 
Glycosylation Site N251 for HA-1 and -2 
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Figure3 Examples of Tandem Mass Spectra Taken from pLabel Showing Matches to 
Peptides Included Glycosylation Site N423 for HA-1 and -2. 
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Figure 4 Tandem Mass Spectra Taken from pLabel Showing Matches to Peptides Included 
Glycosylation Site N459 for HA-1 and -2. 
Appendix D  
There are two ways to calculate glycosylation occupancy: 1. Spectra Number. 2. Peak Area. In 
Appendix D, I attached the graph obtained with peak area marked on top. These numbers are 
sufficient to calculate the glycosylation occupancy of each site in HA-1. However, the results from 
peak area are not consistent with the ones from spectra number counting method. Since our column 
is losing the ability to efficiently separate sample slurry, we believe the spectra number counting 
method is more accurate.  
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Figure 1 The Calculation of N32GT Glycosylation Occupancy in HA-1 Based On Peak Area.   
 
Figure 2 The Calculation of N48AT Glycosylation Occupancy in HA-1 Based On Peak Area.   
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Figure 3 The Calculation of N251DT Glycosylation Occupancy in HA-1 Based On Peak Area.   
 
Figure 4 The Calculation of N423WT Glycosylation Occupancy in HA-1 Based On Peak Area.   
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Figure 5 The Calculation of N459NT Glycosylation Occupancy in HA-1 Based On Peak Area.   
 
 
